Received: 16 December 2019
DOI: 10.1111/cpsp.12355
|
Revised: 20 April 2020
|
Accepted: 30 April 2020
L I T E R AT U R E R E V I E W
Defining response and nonresponse to posttraumatic stress
disorder treatments: A systematic review
Tracey Varker1 | Dzenana Kartal1 | Loretta Watson1 | Isabella Freijah1 |
Meaghan O’Donnell1 | David Forbes1 | Andrea Phelps1 | Malcolm Hopwood2
Alexander McFarlane3 | John Cooper1 | Darryl Wade1 | Richard Bryant4 |
Mark Hinton1
|
1
Phoenix Australia - Centre for
Posttraumatic Mental Health, Department
of Psychiatry, Centre for Posttraumatic
Mental Health, University of Melbourne,
Carlton, Vic., Australia
2
Department of Psychiatry, University of
Melbourne, Carlton, Vic., Australia
3
Centre for Traumatic Stress Studies, The
University of Adelaide, Adelaide, SA,
Australia
4
School of Psychology, The University of
New South Wales, Sydney, NSW, Australia
Correspondence
Tracey Varker Phoenix Australia, Alan
Gilbert Building, 161 Barry Street, Carlton,
Vic. 3053, Australia.
Email: tvarker@unimelb.edu.au
Funding information
Centenary of Anzac Centre
Abstract
There is currently no uniform definition of treatment response for posttraumatic
stress disorder (PTSD) to guide researchers and clinicians in the area of posttraumatic mental health. The aim of this systematic review was to explore the operationalization of PTSD treatment response, by reviewing and synthesizing the key
criteria used to define treatment response and treatment nonresponse in published
trials. Randomized controlled trials (RCTs) assessing the effectiveness of first-line
interventions for PTSD were identified for inclusion. Of those, 143 trials provided
226 definitions of treatment response, grouped under five main categories: treatment
response (n = 181), remission (n = 23), recovery (n = 5), treatment nonresponse
(n = 5), and worsening (n = 12). Overall, the results showed the PTSD field utilizes
diverse and interchangeable operational definitions of treatment response and nonresponse, indicating a need for more precise conceptual definitions and operational
criteria. A set of operational research definitions are presented in order to advance
the PTSD treatment field.
KEYWORDS
pharmacological interventions, posttraumatic stress disorder, psychological interventions,
treatment nonresponse, treatment response
1
|
IN T RO D U C T ION
Posttraumatic stress disorder (PTSD) is precipitated by exposure to traumatic events and consists of symptoms of intrusion, avoidance, arousal, negative cognitions, and negative
mood (American Psychiatric Association; APA, 2013). PTSD
affects approximately 6.8%–9.2% of adults during their lifetime (Kessler et al., 2005; McEvoy, Grove, & Slade, 2011).
However, lifetime prevalence estimates are much higher for
interpersonal trauma (e.g., rape or torture), as well as combat
and military-related trauma (Breslau, Peterson, Poisson,
Schultz, & Lucia, 2004; Goldberg et al., 2016). PTSD is
also associated with significant mental and physical distress, impairments in functioning, and reduced quality of
life (Nemeroff et al., 2006; Olatunji, Cisler, & Tolin, 2007;
Rodriguez, Holowka, & Marx, 2012).
Multiple international guidelines for the treatment of
PTSD recommend trauma-focused cognitive behavioral therapies as first-line interventions (Forbes et al., 2010). Overall,
trauma-focused treatments have demonstrated effectiveness
© 2020 American Psychological Association. Published by Wiley Periodicals LLC, on behalf of the American Psychological Association.
All rights reserved. For permissions, please email: permissions@wiley.com
Clin Psychol Sci Pract. 2020;00:e12355.
https://doi.org/10.1111/cpsp.12355
wileyonlinelibrary.com/journal/cpsp
|
1 of 36
2 of 36
|
(Larsen, Fleming, & Resick, 2019), but many individuals fail
to improve (Koek et al., 2016). A significant proportion of
those who complete a course of psychological or pharmacological treatment still meet criteria for PTSD or are left with
residual symptoms (Larsen et al., 2019). Nonresponse to psychotherapies is even higher in military or refugee populations
(Gerger, Munder, & Barth, 2014; Steenkamp, Litz, Hoge, &
Marmar, 2015).
Despite widespread recognition of the complexity relating to recovery from PTSD, the treatment outcome literature is difficult to interpret because there is a lack of clear
guidance on what constitutes treatment response or nonresponse (Forbes et al., 2019; Sippel, Holtzheimer, Friedman,
& Schnurr, 2018). Efforts to provide clarity in this space
have conceptualized response to treatment as a continuum,
ranging from nonresponse to response, remission, and recovery (Smith-Apeldoorn, Veraart, & Schoevers, 2019).
Nonresponse is defined as achieving minimal to no symptomatic improvement at post-treatment; treatment response
is typically defined as a significant pre- to post-treatment
symptom reduction (usually with the presence of residual
symptoms); remission is considered improvement to, or attainment of, the asymptomatic stage of the disorder (i.e.,
no longer meeting formal diagnostic criteria with minimal
residual symptoms); recovery is sustained remission; and
worsening (including relapse) is usually defined as the exacerbation, deterioration, persistence, or return of clinically
significant symptoms during treatment (Smith-Apeldoorn
et al., 2019). Of note, the terms treatment nonresponse, treatment resistance, and treatment refractory (i.e., occurrence
of an inadequate response following adequate treatment;
McFarlane, 2019) are terms often used interchangeably (for a
more detailed discussion, see Smith-Apeldoorn et al., 2019).
Another common conceptualization of response to treatment
is loss of diagnosis, defined as the absence of a PTSD diagnosis at post-treatment (Smith-Apeldoorn et al., 2019).
In contrast to clinical practice, in research settings treatment outcomes are typically defined in terms of symptom
changes, rather than functional outcomes (Smith-Apeldoorn
et al., 2019). Furthermore, when it comes to defining response as an absolute symptom reduction, the decrease in
symptoms determined to be statistically significant can fail to
translate into clinically meaningful improvement in the dayto-day function of treatment seekers. Many still meet criteria
for a diagnosis of PTSD and have persistent problems (Berger
et al., 2009).
In addition to the criticism of measuring treatment outcomes in terms of symptom reductions only, other important
targets of therapy are overlooked. These include patient-defined treatment goals, quality of life improvement, and
social and economic outcomes (e.g., cost-effectiveness;
Cuijpers, 2019). While most research has concentrated on
PTSD symptom reduction, these additional treatment targets
VARKER ET AL.
Public Health Significance
This systematic review synthesized and categorized
the ways that PTSD treatment response and nonresponse are operationalized in the literature. The
findings revealed diversity and interchangeability
among definitions, which impedes the interpretability of treatment outcome research. Clear definitions
of these concepts are necessary to inform PTSD
treatment planning.
should be incorporated into treatment priorities, preferably
through a shared patient–clinician clinical decision-making
process.
1.1 | Previous attempts to define PTSD
treatment response and nonresponse
The issue of response and nonresponse to PTSD treatment
has attracted growing interest over the last decade. Most recently, Sippel et al. (2018) argued that it is critical to develop
evidence-based benchmarks and differentiate between treatment response and nonresponse. Specifically, they proposed
that an operational definition of treatment resistance will
stimulate and guide the development and evaluation of novel
treatments; will facilitate the examination of the biological
mechanisms underlying poor treatment response; and will
assist clinicians to better identify treatment-resistant patients
(Sippel et al., 2018). The authors proposed a conceptual
staged model of treatment-resistant PTSD that incorporates
treatment nonresponse criteria. However, their criteria were
not based on a systematic review of the evidence. Others have
also discussed the issue of differential definitions for treatment response, nonresponse, and resistance. In particular,
Koek et al. (2016) reviewed pharmacological interventions
for the treatment of patients whose symptoms were resistant to standard PTSD treatments. As part of their review, the
authors extracted definitions of prior treatment failure, but
conclusions relating to the definition of treatment response or
nonresponse were not provided. The current review will examine how treatment nonresponse including treatment resistance is operationalized and defined in PTSD treatment RCTs.
The failure to define what constitutes treatment response
from nonresponse in PTSD stands in stark contrast to work
in other mental health disorders such as depression (Frank
et al., 1991) and obsessive–compulsive disorder (Pallanti
et al., 2002), where definitions have been established in order to
clearly differentiate and describe the quality of response to treatment. The categories most often reported include treatment response, partial or nonresponse, treatment resistance, remission,
|
VARKER ET AL.
full or partial recovery, and relapse. Operationalization of these
categories for PTSD treatment will ultimately help to inform the
development of a clinical algorithm, which will guide treatment
and optimize treatment decisions in both clinical practice and
clinical trials. To the best of our knowledge, there has been no
review that has systematically examined how PTSD treatment
response and nonresponse are operationalized in both psychological and pharmacological PTSD treatment trials. The aim of
this study is to systematically review how PTSD treatment response and nonresponse have been operationalized, and to propose definitions for these constructs to increase the consistency
with which they are applied in research and clinical practice.
2
|
M ET H OD
The findings of this review were reported in accordance with
Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA; Moher, Liberati, Tetzlaff, & Altman,
2009). The study protocol was registered with Prospero (registration ID CRD420191196701). The research question was
formulated using the Population, Intervention, Comparison,
and Outcome (PICO; Schardt, Adams, Owens, Keitz, &
Fontelo, 2007) framework in order to structure, contain,
and set the scope for the question. Inclusion criteria were as
follows:
1. Peer-reviewed randomized controlled trials (RCTs) published in English;
2. Trials that assessed the efficacy of guideline-recommended first-line psychological, pharmacological, or
combined interventions;
3. Treatment that included individual and face-to-face mode
of delivery;
4. Sample that comprised adults with a primary diagnosis of
PTSD.
Guideline-recommended first-line psychological interventions included in this review were as follows: cognitive
behavior therapy (CBT), cognitive processing therapy (CPT),
cognitive therapy (CT), prolonged exposure (PE), eye movement desensitization and reprocessing (EMDR), brief eclectic psychotherapy (BEP), narrative exposure therapy (NET),
and written narrative exposure therapy. First-line pharmacological interventions recommended by treatment guidelines
include sertraline, paroxetine, fluoxetine, and venlafaxine
(see Table S1 for more details).
The exclusion criteria were any first-line interventions
targeting only one of the PTSD symptoms in isolation (e.g.,
nightmares); interventions that involved only one component
of a first-line treatment (i.e., not a full protocol); or interventions delivered in group format or via virtual reality or
telehealth/Internet modalities.
|
2.1
3 of 36
Search strategy
Relevant RCTs published from inception to December 21,
2018, were identified via PsycINFO, EMBASE, PubMed
(including MEDLINE), CINAHL, and Cochrane Central
Register of Controlled Trials (CENTRAL). An example
search strategy is provided in Table S2.
|
2.2
Data extraction
Trials were selected using a two-stage process: title and
abstract screening and full-text assessment. Both stages
were undertaken using Covidence, an online systematic
review information management system (Veritas Health
Innovation).
|
2.3
Operational definition synthesis
The operational definitions of treatment response and nonresponse were identified and categorized based on the author's own descriptions rather than a priori definitions. Using
this bottom-up approach, five categories emerged: treatment
response, remission, recovery, treatment nonresponse, and
worsening. Of note, these categories loosely matched the
conceptualizations of treatment response and nonresponse
outlined in Smith-Apeldoorn et al. (2019).
Once placed in a response category, definitions were further subcategorized based on details reported in the studies.
These further categories distinguished between (a) use of a
clinician- and self-rated measures; and (b) how studies defined change in PTSD outcomes (i.e., score or percentage
reduction, cutoff score, a statistically derived formula, or diagnostic criteria plus functional assessments).
|
2.4
Inter-rater reliability
Two independent reviewers completed all screenings. Interrater reliability calculated as a percent agreement (Kottner
& Streiner, 2011) was high (99.6% for the Stage 1: title/
abstract screening, and 93.6% for Stage 2: full-text assessments). In both stages, disagreements were resolved by discussion, and where necessary, arbitration was conducted by
another two reviewers. Data extraction was conducted by
two reviewers.
3
|
RESULTS
From a yield of 10,183 records, 4,679 records were screened
on title and abstract and 372 records were screened on
4 of 36
|
VARKER ET AL.
Eligibility
3.1
|
Trial descriptions
The trials included in the qualitative synthesis were from
the United States (n = 76, 53.1%), Western Europe (n = 35,
24.5%), Australia (n = 7, 4.9%), Asia (n = 6, 4.2%), or other
countries (n = 15, 10.5%; see Table 1 for further details).
The greatest proportion of trials involved samples reporting mixed types of trauma (n = 73, 51.1%). Other trauma
types included military-related trauma (n = 30, 21.0%), manmade disasters including wars, displacement, and terrorism
(n = 18, 12.6%), and interpersonal violence including sexual
violence (n = 8, 5.6%). The majority of trials were conducted
post-2010 (n = 84; 58.7%). Approximately one third of trials
Records identified through database searching
PsycINFO (n = 1639), EMBASE (n = 2308), CINAHL (n
= 1054), PubMed (n = 2201), Central (n = 2981).
n = 10183
Records after duplicates removed
(n = 4679)
Screening
Identification
full-text (see the PRISMA flowchart presented in Figure 1).
Of those, 192 trials with a total number of 13,789 participants were eligible for inclusion. There was an increase in the
use of operational definitions of treatment response or nonresponse over time (pre-2000:7% of studies had definitions;
from 2000 to 2010:33% of studies had definitions; and post2010:60% of studies had definitions). Despite this increase,
40% of trials published post-2010 still failed to operationalize response to treatment. Overall, operational definitions of
treatment response or nonresponse were provided in the 143
trials that were included in the qualitative synthesis. The trials that did not provide definitions (n = 49) were not included
in the qualitative synthesis.
Records screened
(n = 4679)
Full-text articles assessed for eligibility
(n = 372)
Included
Studies eligible for inclusion in qualitative
synthesis
(n = 192)
Studies with definitions
(n = 143)*
Studies without definitions
(n = 49)
*Studies that contained more than one definition were counted once.
FIGURE 1
PRISMA flowchart
Records excluded
(n = 4307)
Full-text articles excluded,
with reasons (n = 180)
Not a guideline
recommended
intervention (n = 68)
Secondary analysis (not
of interest; n = 62)
Children or adolescents
(n = 22)
Not an RCT (n = 11)
Not a peer reviewed
paper (n = 7)
Paper not in English
(n = 6)
Wrong outcomes (n = 4)
Study authors definitions of treatment response including loss of diagnosis, remission, recovery, treatment nonresponse, and worsening to PTSD intervention (n = 143)
Authora
Country
N (Male %)
Trauma type
Intervention
Treatment response (n = 98)
Loss of
diagnosis
(n = 83)
Remission and Recovery
(n = 28)
Treatment nonresponse and
worsening including relapse
(n = 17)
Acarturk et al. (2015)
Turkey
29 (24.1%)
Refugees/displacement
EMDR versus WL
n/r
Cutoff ≥ 33
points on IES-R
(n/r)
n/r
n/r
Acarturk et al. (2016)
Turkey
98 (25.5%)
Refugees/displacement
EMDR versus WL
n/r
M.I.N.I.
(DSM-IV)
n/r
n/r
Acierno et al. (2016)
US
232 (94.4%)
Military
BA-TE* versus BE-TE* telehealth
≥8.8-point reduction on PCL-M
(DSM-IV)
(Clinically meaningful)
n/r
n/r
n/r
Acierno et al. (2017)
USA
132 (96.2%)
Military
PE versus PE telehealth
≥8.8-point reduction on PCL-M
(DSM-IV)
(Noninferiority margin)
n/r
n/r
n/r
Arntz et al. (2007)
Netherlands
67 (34.3%)
Mixed trauma
IE versus IE + IR
n/r
n/r
Cutoff ≤ 20 points on
PSS-SR (DSM-III-R)
(Recovery)
n/r
Asukai et al. (2010)
Japan
24 (12.5%)
Mixed trauma
PE versus TAU
≥15-point reduction on CAPS
(DSM-IV)
(Clinically meaningful)
CAPS (DSM-IV)
Cutoff < 20 points on
CAPS (DSM-IV)
(Total remission)
Cutoff = 20–25 points on
CAPS (DSM-IV)
(Near remission)
n/r
Back et al. (2006)
USA
94 (54.3%)
Mixed trauma
SRT versus PBO
≥30% reduction on CAPS (DSM-IV)
AND
Rating of 1 or 2 on CAPS Question 20
(DSM-IV)
n/r
n/r
Did not meet response
definition
(Nonresponder)
Back et al. (2019)
USA
81 (90.1%)
Military
COPE versus relapse prevention
n/r
n/r
Cutoff = 50 points on
CAPS (DSM-IV)
(Remission)
n/r
Beidel et al. (2011)
USA
35 (100%)
Military
Exposure* versus TMT
Rating of 1 or 2 on CGI-I
n/r
n/r
Rating of ≥ 3 on CGI-I
(Worsening)
Belleville et al. (2018)
Canada
42 (11.9%)
Sexual assault
CBT versus CBT + IRT
n/r
CAPS
(DSM-IV-TR)
n/r
n/r
VARKER ET AL.
TABLE 1
|
5 of 36
(Continues)
(Continued)
N (Male %)
Trauma type
Intervention
Treatment response (n = 98)
Loss of
diagnosis
(n = 83)
Remission and Recovery
(n = 28)
Treatment nonresponse and
worsening including relapse
(n = 17)
18 (94.4%)
Torture
NET versus PsychEdu
n/r
CIDI (DSM-IV)
n/r
n/r
Blanchard et al.
(2003)
USA
98 (26.9%)
MVA
CBT versus SPT versus WL
n/r
CAPS (DSM-IV)
n/r
Retained full PTSD diagnosis
post-treatment
(Nonresponder)
Brady et al. (2000)
USA
187 (26.7%)
Mixed trauma
SRT versus PBO
≥30% reduction on CAPS (DSMIII-R) AND
Rating of 1 or 2 on CGI-I
(Clinically meaningful)
n/r
n/r
n/r
Bryant et al. (2003)
Australia
58 (48.3%)
Mixed trauma
IE versus IE + CR versus SC
Cutoff < 19 points on CAPS
(DSM-IV) AND
Cutoff < 10 points on BDI-2
(Good end-state functioning)
CAPS (DSM-IV)
n/r
n/r
Bryant et al. (2011)
Thailand
28 (3.6%)
Terrorism
CBT versus TAU
Cutoff < 19 points on CAPS
(DSM-IV) AND
Cutoff < 10 points on BDI-2
(Good end-state functioning)
n/r
n/r
n/r
Bryant et al. (2013)
Australia
70 (45.7%)
Mixed trauma
CBT + SC versus CBT + Skills
Cutoff < 19 points on CAPS
(DSM-IV) AND
Cutoff < 10 points on BDI-2
(Good end-state functioning)
n/r
n/r
n/r
Bryant et al. (2018)
Australia
100 (77%)
Emergency services
CBT versus CBT (brief IE) versus WL
n/r
CAPS (DSM-IV)
n/r
n/r
Buhmann et al. (2018)
Denmark
280 (59%)
Refugee/ displacement
CBT versus SRT + PsychEdu versus
SRT + CBT +PsychEdu versus WL
n/r
Cutoff = 2.5
points on HTQ
(ICD-10 and
DSM-IV)
n/r
n/r
Butollo et al. (2016)
Germany
148 (34%)
Mixed trauma
CPT versus DET
RCI = n/r (PDS and IES-R, DSM-IV)
n/r
PDS (DSM-IV)
(Remission)
RCI (=n/r) changed in
direction of greater
dysfunction (PDS-I,
DSM-IV)
(Worsening)
(Continues)
VARKER ET AL.
Bichescu et al. (2007)
Romania
|
Authora
Country
6 of 36
TABLE 1
(Continued)
Authora
Country
N (Male %)
Trauma type
Intervention
Treatment response (n = 98)
Loss of
diagnosis
(n = 83)
Remission and Recovery
(n = 28)
Treatment nonresponse and
worsening including relapse
(n = 17)
Carletto et al. (2016)
Italy
50 (19%)
Physical illness
EMDR versus RT
n/r
CAPS (DSM-IV)
n/r
n/r
Carlson et al. (1998)
USA
35 (100%)
Military
EMDR versus biofeedback-assisted relaxation
versus TAU
n/r
CAPS (DSM-IV)
n/r
n/r
Cavaljuga et al. (2003)
Bosnia and
Herzegovina
20 (100%)
Military
FLX versus AMI
n/r
Cutoff = 2.5
points on HTQ
(ICD-10 and
DSM-IV)
n/r
n/r
Celik et al. (2011)
Turkey
50 (n/r)
Military
PRX versus AMI
≥30% reduction on CAPS (DSM-IV)
AND
Rating of 1 or 2 on CGI-I
(Clinically meaningful)
n/r
n/r
n/r
Chard (2005)
USA
71 (0%)
CSA
CPT versus MA
Cutoff ≤ 20 points on MPSS (DSMIII) AND
Cutoff ≤ 10 points on BDI-2
(Good end-state functioning)
CAPS (DSM-IV)
n/r
n/r
Chung et al. (2004)
Korea
113 (100%)
Military
SRT versus MRTZ
≥ 30% reduction on CAPS (DSM-IV)
OR
≥ 50% reduction on HAMD-17
(DSM-IV) OR
Rating of 1 or 2 on CGI-I
n/r
n/r
Did not meet response
definition
(Nonresponder)
Cigrang et al. (2017)
USA
67 (74.6%)
Military
PE (brief) versus MCC
n/r
PSS-I (DSM-IV)
n/r
n/r
Cloitre et al. (2002)
USA
58 (0%)
CSA/CPA
Exposure* + STAIR versus WL
Cutoff < 20 points on MPSS-SR
(DSM-IV) AND
Cutoff < 40 points on STAI–S AND
Cutoff < 10 points on BDI
(Good end-state functioning)
CAPS (DSM-IV)
n/r
Increase in CAPS severity
score between baseline and
post-treatment
(Worsening)
VARKER ET AL.
TABLE 1
|
7 of 36
(Continues)
(Continued)
N (Male %)
Trauma type
Intervention
Treatment response (n = 98)
Loss of
diagnosis
(n = 83)
Remission and Recovery
(n = 28)
Treatment nonresponse and
worsening including relapse
(n = 17)
104 (0%)
CSA/CPA
Exposure* + STAIR versus STAIR + SC
versus Exposure* + SC
n/r
CAPS (DSM-IV)
Cutoff < 20 points on
CAPS (DSM-IV)
(Remission)
≥7-point (1 SD) increase
on CAPS severity score
between post-treatment
baseline
(Worsening)
Coffey et al. (2016)
USA
126 (54%)
Mixed trauma
M-PE versus M-PE + MET-PTSD versus
HLS
>2 SD reduction on IES (DSM-IV)
Cutoff = 20.23 points
(Clinically meaningful)
n/r
n/r
n/r
Connor et al. (1999)
USA
54 (9%)
Mixed trauma
FLX versus PBO
Rating of 1 or 2 on Duke Improvement
Scale
n/r
n/r
Did not meet response
definition
(Nonresponder)
Cottraux et al. (2008)
France
60 (30%)
Mixed trauma
CBT versus RST
Cutoff < 44 points on PCL-S
(DSM-IV)
(General criterion of improvement)
Cutoff < 35 points on PCL-S
(DSM-IV)
(More stringent criterion of
improvement)
n/r
n/r
n/r
Crocker et al. (2018)
USA
74 (87.8%)
Military
CPT versus CPT (Smart)
Cutoff < 50 points on PCL-S
(DSM-IV) AND
≥10-point reduction on PCL-S
(DSM-IV)
(Clinically meaningful)
n/r
n/r
n/r
Davidson et al. (2001)
USA
208 (22.1%)
Mixed trauma
SRT versus PBO
≥30% reduction on CAPS (DSMIII-R) AND
Rating of 1 or 2 on CGI-I
(Clinically meaningful)
n/r
n/r
n/r
Davidson et al. (2005)
USA
62 (49.2%)
Mixed trauma
FLX versus PBO
n/r
n/r
n/r
Rating of ≥4 on GCI-I OR
≥2-point increase on CGI-I
(Relapse)
Davidson, Baldwin,
et al. (2006)
Multiple countries (56
sites)
329 (45.9%)
Mixed trauma
VLFX versus PBO
≥30% reduction on CAPS (DSM-IV)
n/r
Cutoff ≤ 20 points on
CAPS (DSM-IV)
(Remission)
n/r
(Continues)
VARKER ET AL.
Cloitre et al. (2010)
USA
|
Authora
Country
8 of 36
TABLE 1
(Continued)
Authora
Country
N (Male %)
Trauma type
Intervention
Davidson, Rothbaum,
et al. (2006)
USA
Treatment nonresponse and
worsening including relapse
(n = 17)
n/r
n/r
Cutoff ≤ 20 points on
CAPS (DSM-IV)
(Remission)
n/r
de Bont et al. (2013)
Netherlands
10 (20%)
Mixed trauma
PE versus EMDR
n/r
CAPS (DSM-IV)
n/r
n/r
De Kleine et al. (2012)
Netherlands
N = 75 (M: 19.4%)
Mixed trauma
PE + PBO versus PE + DCS
≥10-point reduction on CAPS
(DSM-IV-TR)
n/r
Cutoff < 20 points on
CAPS
(Remission)
n/r
Difede et al. (2007)
USA
31 (97%)
Terrorism
CBT versus TAU
≥10-point reduction on CAPS
(DSM-IV-TR)
(Clinically meaningful)
CAPS
(DSM-IV-TR)
n/r
n/r
Dunne et al. (2012)
Australia
26 (50%)
MVA
CBT (TF) versus WL
RCI = 7.8 points (PDS, DSM-IV)
(Clinically meaningful)
SCID (DSM-IV)
n/r
n/r
Ehlers et al. (2003)
UK
85 (n/r)
MVA
CT versus SHB versus Repeated assessments
≥50% reduction on PDS (DSM-IV)
Cutoff < 14 points on PDS (DSM-IV)
AND
Cutoff < 2 points on CAPS Global
Severity (DSM-IV) AND
Cutoff < 12 points on BDI AND
Cutoff < 12 points on BAI
(Good end-state functioning)
PDS (DSM-IV)
AND
Cutoff ≥ 14
points on PDS
(DSM-IV)
OR
CAPS (DSM-IV)
AND
Rating of ≥ 2 on
CAPS global
severity scale
(DSM-IV)
n/r
n/r
Ehlers et al. (2005)
UK
28 (46.4%)
Mixed trauma
CT versus WL
≥50% reduction on PDS (DSM-IV)
Cutoff < 14 points on PDS (DSM-IV)
AND
Cutoff < 2 points on PDS-distress
scale (DSM-IV) AND
Cutoff < 12 points on BDI AND
Cutoff < 12 points on BAI
(Good end-state functioning)
PDS (DSM-IV)
AND
Cutoff > 2 points
on PDS-distress
scale (DSM-IV)
AND
Cutoff ≥ 14
points on PDS
(DSM-IV)
n/r
n/r
(Continues)
9 of 36
538 (n/r)
Mixed trauma
VLFX versus SRT versus PBO
Remission and Recovery
(n = 28)
|
Treatment response (n = 98)
Loss of
diagnosis
(n = 83)
VARKER ET AL.
TABLE 1
(Continued)
N (Male %)
Trauma type
Intervention
Treatment response (n = 98)
Loss of
diagnosis
(n = 83)
Remission and Recovery
(n = 28)
Treatment nonresponse and
worsening including relapse
(n = 17)
Ehlers et al. (2014)
UK
121 (41.3%)
Mixed trauma
CT (intensive) versus CT versus SC versus
WL
n/r
CAPS (DSM-IV)
AND
Cutoff ≥ 1 for
both frequency
and intensity
on CAPS
(DSM-IV) AND
Rating of 1 or 2
on CAPS global
severity scale
(DSM-IV)
Cutoff < 20 points on
CAPS (DSM-IV) AND
Cutoff < 11 points on
PDS (DSM-IV)
(Remission)
>6.15-point increase on PDS
(DSM-IV) from baseline
AND
>10-point increase on CAPS
(DSM-IV) from baseline
(Worsening)
Ertl et al. (2011)
Uganda
85 (44.7%)
Mixed trauma
NET versus academic catch-up versus WL
≥15-point reduction on CAPS
(DSM-IV)
(Clinically meaningful)
CAPS (DSM-IV)
n/r
n/r
Fecteau et al. (1999)
Canada
20 (30%)
MVA
CBT versus WL
RCI = 11.09 points (CAPS, DSM-IV)
(Clinically meaningful)
CAPS (DSM-IV)
n/r
n/r
Feeny et al. (2002)
USA
72 (0%)
Mixed trauma
PE versus SIT versus PE + SIT versus WL
Cutoff ≤ 20 points on PSS-I (DSMIII-R) AND
Cutoff ≤ 40 points on STAI-S AND
Cutoff ≤ 10 points on BDI
(Good end-state functioning)
PSS-I
(DSM-III-R)
n/r
n/r
Feng et al. (2018)
China
240 (29.6%)
Mixed trauma
SRT + S-TEAS versus CBT + S-TEAS
versus SRT + A-TEAS versus
CBT + A-TEAS
≥30% reduction on CAPS (DSM-IV)
(Clinically meaningful)
n/r
Cutoff ≤ 20 points on
CAPS (DSM-IV)
(Remission)
n/r
VARKER ET AL.
(Continues)
|
Authora
Country
10 of 36
TABLE 1
(Continued)
Authora
Country
N (Male %)
Trauma type
Intervention
Treatment response (n = 98)
Loss of
diagnosis
(n = 83)
Remission and Recovery
(n = 28)
Treatment nonresponse and
worsening including relapse
(n = 17)
Feske et al. (2008)
USA
21 (0%)
Mixed trauma
PE versus TAU
RCI = n/r (PDS-I and IES-R,
DSM-IV)
≥2 SD reduction on PDS-I and IES-R
(DSM-IV)
Cutoff = n/r
(Clinically meaningful)
n/r
Reliable improvement
AND
PDS-I and IES-R scores
move from statistically
belonging to the
dysfunctional population
distribution at pretest
to the functional
population distribution
at posttest
(Recovery)
RCI (=n/r) changed in
direction of greater
dysfunction (PDS-I,
DSM-IV)
(Worsening)
Foa et al. (1991)
USA
45 (0%)
Sexual assault
PE versus SIT versus SC versus WL
>2 SD decrease (assessment measure/
score n/r)
Cutoff = n/r
(Clinically meaningful)
Clinical
interview
(DSM-III)
n/r
n/r
Foa et al. (1999)
USA
96 (0%)
Mixed trauma
PE versus SIT versus PE + SIT versus WL
Cutoff ≤ 20 points on PSS-I (DSMIII-R) AND
Cutoff ≤ 40 points on STAI-S AND
Cutoff ≤ 10 points on BDI
(Good end-state functioning)
PSS-I
(DSM-III-R)
n/r
n/r
Foa et al. (2013)
USA
165 (65.5%)
Mixed trauma
PE + PBO versus PE + NLTX versus
SC + NLTX versus SC + PBO
Cutoff ≤ 10 points on PSS-I
(DSM-IV)
(Low severity)
n/r
n/r
n/r
Foa et al. (2018)
USA
370 (88%)
Military
PE (intensive) versus PE versus PCT versus
MCC
One-half SD decrease
Cutoff = 3.18 points (PSS-I,
DSM-IV-TR)
Cutoff = 7.9 points (PCL-S,
DSM-IV-TR)
(Minimal clinically important
difference)
PSS-I
(DSM-IV-TR)
n/r
n/r
Fonzo et al. (2017)
USA
66 (34.8%)
Mixed trauma
PE versus WL
n/r
n/r
Cutoff < 20 points on
CAPS (DSM-IV)
(Remission)
n/r
VARKER ET AL.
TABLE 1
|
11 of 36
(Continues)
(Continued)
Loss of
diagnosis
(n = 83)
Treatment response (n = 98)
Forbes et al. (2012)
Australia
59 (96.6%)
Military
CPT versus TAU
>12-point reduction on CAPS
(DSM-IV)
(Clinically meaningful)
CAPS (DSM-IV)
Cutoff < 20 points on
CAPS (DSM-IV)
(Remission)
n/r
Ford et al. (2018)
USA
31 (100%)
Military
PE versus TARGET
>12-point reduction on CAPS
(DSM-IV)
(Clinically meaningful)
CAPS (DSM-IV)
n/r
n/r
Friedman et al. (2007)
USA
169 (79.9%)
Mixed trauma
SRT versus PBO
≥30% reduction on CAPS (DSMIII-R) AND
Rating of 1 or 2 on CGI-I
(Clinically meaningful)
n/r
n/r
n/r
Galovski et al. (2012)
USA
100 (31%)
Mixed trauma
M-CPT versus SMDT
Cutoff ≤ 20 points on PDS AND
Cutoff ≤ 18 points on BDI-2
(Good end-state functioning)
CAPS (DSM-IV)
n/r
n/r
Gersons et al. (2000)
Netherlands
42 (88.1%)
Emergency Services
BEP versus WL
n/r
SI-PTSD
(DSM-III-R)
n/r
n/r
Haller et al. (2016)
USA
123 (88.6%)
Mixed trauma
I-CBT versus M-CPT
≥10-point reduction on PCL-C
(DSM-IV)
(Clinically meaningful)
≥5-point reduction on PCL-C
(DSM-IV)
(Minimum threshold)
n/r
n/r
n/r
Harned et al. (2014)
USA
26 (0%)
Mixed trauma
DBT-PE* + DBT versus DBT
RCI = 10.5 points (PSS-I, DSM-IV)
>2 SD reduction on PSS-I (DSM-IV)
Cutoff ≤ 14.9 points
(Clinically meaningful)
n/r
PSS-I (DSM-IV) AND
Achieving both reliable
and clinically significant
improvement
(Recovery)
n/r
Hensel-Dittmann et al.
(2011)
Germany
28 (n/r)
Refugee/displacement
NET versus SIT
n/r
CAPS (DSM-IV)
n/r
n/r
Hertzberg et al. (2000)
USA
12 (100%)
Military
FLX versus PBO
Rating of 1 or 2 on Duke Improvement
Scale
n/r
n/r
Rating of > 2 on Duke
Improvement Scale
(Nonresponder)
Remission and Recovery
(n = 28)
Treatment nonresponse and
worsening including relapse
(n = 17)
VARKER ET AL.
(Continues)
|
N (Male %)
Trauma type
Intervention
Authora
Country
12 of 36
TABLE 1
(Continued)
N (Male %)
Trauma type
Intervention
Treatment response (n = 98)
Hien et al. (2015)
USA
69 (19%)
Mixed trauma
SRT + SS versus PBO + SS
Hinton et al. (2005)
USA
Remission and Recovery
(n = 28)
Treatment nonresponse and
worsening including relapse
(n = 17)
>15-point reduction on CAPS
(DSM-IV-TR)
(Clinically meaningful)
n/r
n/r
n/r
40 (40%)
Refugees/displacement
CBT versus delayed treatment
>15-point reduction on CAPS
(DSM-IV)
(Clinically meaningful)
CAPS (DSM-IV)
n/r
n/r
Hogberg et al. (2007)
Sweden
24 (79.2%)
Occupation-based
EMDR versus WL
>2 SD reduction on IES (DSM-IV)
Cutoff = n/r
(Clinically meaningful)
SCID (DSM-IV)
n/r
n/r
Ironson et al. (2002)
USA
22 (22.7%)
Mixed trauma
EMDR versus PE
>70% reduction on PSS-SR
(DSM-III-R)
n/r
n/r
n/r
Jacob et al. (2014)
Rwanda
76 (43 widows; 33 orphans; 7.9%)
Refugees/displacement
NET versus WL
RCI = 17.7 points (CAPS,
DSM-IV-TR)
(Clinically meaningful)
CAPS
(DSM-IV-TR)
n/r
n/r
Karatzias et al. (2011)
UK
46 (43.5%)
Mixed trauma
EMDR versus EFT
>2 SD reduction on CAPS and PCL-C
(DSM-IV)
Cutoff = n/r
(Clinically meaningful)
n/r
n/r
n/r
Kozel et al. (2018)
USA
103 (n/r)
Military
CPT + rTMS versus CPT + sham
Cutoff = 7.9 points (PCL, DSM-IV)
Cutoff = 10.4 points (CAPS,
DSM-IV)
(Minimally clinically important
difference)
n/r
n/r
n/r
Langkaas et al. (2017)
Norway
65 (42%)
Mixed trauma
PE versus IR
RCI = 8 points (PSS-I, DSM-IV)
AND
Cutoff ≤ 23 points (PSS-I, DSM-IV)
(Clinically meaningful)
n/r
Clinically significant
differences based on
RCI were used to
differentiate between
recovered, improved,
not reliably changed,
and deteriorated
(Recovery)
RCI (= 8) changed in
direction of greater
dysfunction (PSS-I,
DSM-IV)
(Worsening)
Lee et al. (2002)
n/r
24 (54.2%)
Mixed trauma
PE + SIT versus EMDR
>2 SD reduction on IES (DSM-III-R)
Cutoff < 37 points
(Clinically meaningful)
SI-PTSD
(DSM-III-R)
n/r
n/r
|
Loss of
diagnosis
(n = 83)
Authora
Country
VARKER ET AL.
TABLE 1
13 of 36
(Continues)
(Continued)
N (Male %)
Trauma type
Intervention
Treatment response (n = 98)
Loss of
diagnosis
(n = 83)
Remission and Recovery
(n = 28)
Treatment nonresponse and
worsening including relapse
(n = 17)
Li et al. (2017)
China
72 (87.5%)
Mixed trauma
SRT versus PBO
≥30% reduction on IES-R (DSM-IV)
n/r
n/r
n/r
Lindauer et al. (2008)
Netherlands
20 (50%)
Mixed trauma
BEP versus WL
n/r
SI-PTSD
(DSM-IV)
n/r
n/r
Lindauer, Gersons
et al. (2005)
Netherlands
24 (45.8%)
Mixed trauma
BEP versus WL
n/r
SI-PTSD
(DSM-IV)
n/r
n/r
Lindauer, Vlieger et al.
(2005)
Netherlands
18 (44.4%)
Mixed trauma
BEP versus WL
n/r
SI-PTSD
(DSM-IV)
n/r
n/r
Litz et al. (2012)
USA
26 (100%)
Military
Exposure* + PBO versus Exposure* + DCS
≥10-point reduction on CAPS
(DSM-IV)
CAPS (DSM-IV)
n/r
n/r
Maercker et al. (2006)
Germany
48 (23.8%)
MVA
CBT versus WL
n/r
CAPS (DSM-IV)
n/r
n/r
Maieritsch et al. (2016)
USA
90 (93.3%)
Military
CPT versus CPT telehealth
≥10-point reduction on CAPS
(DSM-IV-TR)
n/r
n/r
n/r
Marcus et al. (1997)
USA
67 (20.9%)
Mixed trauma
EMDR versus TAU
n/r
n/r (DSM-III-R)
n/r
n/r
Markowitz et al. (2015)
USA
110 (30%)
Mixed trauma
PE versus IPT versus RT
>30% reduction on CAPS (DSM-IV)
>15-point reduction on CAPS
(DSM-IV)
(Clinically meaningful)
n/r
Cutoff < 20 points on
CAPS (DSM-IV)
(Remission)
n/r
VARKER ET AL.
(Continues)
|
Authora
Country
14 of 36
TABLE 1
(Continued)
Authora
Country
N (Male %)
Trauma type
Intervention
Treatment response (n = 98)
Loss of
diagnosis
(n = 83)
Remission and Recovery
(n = 28)
Treatment nonresponse and
worsening including relapse
(n = 17)
87 (64%)
Mixed trauma
PE + IE versus CR versus PE + IE + CR
versus RT
>50% reduction on PSS (DSM-III-R)
AND
Cutoff ≤ 7 points on BDI AND
Cutoff ≥ 35 points on STAI
(Good end-state functioning)
≥2 SD reduction on CAPS
(DSM-III-R)
Cutoff = n/r AND
≥2 SD reduction on IES (DSM-III-R)
Cutoff = n/r AND
≤3 on GHQ Global Improvement
Subscale
CAPS
(DSM-III-R)
n/r
n/r
Marshall et al. (2001)
USA
563 (31.6%)
Mixed trauma
PRX (20 mg) versus PRX (40 mg) versus
PBO
Rating of 1 or 2 on CGI-I
n/r
n/r
n/r
Marshall et al. (2007)
USA
52 (32.7%)
Mixed trauma
PRX versus PBO
Rating of 1 or 2 on CGI-I
CAPS (DSM-IV)
n/r
n/r
Martenyi et al. (2002)
Belgium, Bosnia,
Croatia, Yugoslavia,
Israel and South
Africa
301 (81%)
Mixed trauma
FLX versus PBO
≥50% reduction on TOP-8 (DSM-IV)
AND
Rating of 1 or 2 on CGI-S
n/r
n/r
n/r
Martenyi et al. (2007)
USA
411 (28.5%)
Mixed trauma
FLX (20 mg/day) versus FLX (40 mg/day)
versus PBO
≥50% reduction on TOP-8 (DSM-IV)
AND
Rating of 1 or 2 on CGI-S AND
No longer meeting diagnostic criteria
on CAPS (DSM-IV)
CAPS (DSM-IV)
n/r
n/r
McDonagh et al.
(2005)
USA
74 (0%)
CSA
CBT versus PCT versus WL
n/r
CAPS (DSM-IV)
n/r
n/r
McGovern et al. (2011)
USA
53 (43.4%)
Mixed trauma
I-CBT + TAU versus AC + TAU
≥15 point reduction on CAPS (DSM
n/r)
(Clinically meaningful)
CAPS (DSM n/r)
n/r
n/r
|
Marks et al. (1998)
UK
VARKER ET AL.
TABLE 1
15 of 36
(Continues)
(Continued)
Remission and Recovery
(n = 28)
Treatment nonresponse and
worsening including relapse
(n = 17)
Treatment response (n = 98)
McGovern et al. (2015)
USA
221 (40.7%)
Mixed trauma
I-CBT + TAU versus AC + TAU versus TAU
≥15-point reduction on CAPS
(DSM-IV)
(Clinically meaningful)
n/r
n/r
n/r
McLay et al. (2017)
USA
81 (96.3%)
Military
Exposure therapy* versus VR-EXP
≥30% reduction on CAPS (DSM-IV)
n/r
Cutoff ≤ 20 points on
CAPS (DSM-IV)
(Remission)
n/r
Mills et al. (2012)
Australia
103 (37.9%)
Mixed trauma
COPE versus TAU
≥15 point reduction on CAPS (DSMIV-TR) AND
1-point change on CIDI
(Clinically meaningful)
CAPS
(DSM-IV-TR)
n/r
n/r
Monson et al. (2006)
USA
60 (90%)
Military
CPT versus WL
RCI = 12-point (CAPS, DSM-IV-TR)
CAPS
(DSM-IV-TR)
n/r
n/r
Morland et al. (2015)
USA
126 (0%)
Mixed trauma
CPT versus CPT telehealth
≥10-point reduction on CAPS
(DSM-IV)
(Clinically meaningful)
CAPS (DSM-IV)
n/r
n/r
Mueser et al. (2008)
USA
108 (21.3%)
Mixed trauma
CBT versus TAU
n/r
CAPS (DSM-IV)
n/r
n/r
Mueser et al. (2015)
USA
201 (33%)
n/r
CBT versus CBT (brief)
n/r
CAPS (DSM-IV)
n/r
n/r
Nacasch et al. (2015)
Israel
40 (61.5%)
Mixed trauma
PE versus PE (brief IE)
RCI = 7 points (PSS-I, DSM-IV)
(Clinically meaningful)
n/r
n/r
n/r
Neuner et al. (2004)
Uganda
43 (37.2%)
Refugees/displacement
NET versus SC versus PsychEdu
n/r
CIDI (DSM-IV)
n/r
n/r
Neuner et al. (2008)
Uganda
277 (48.7%)
Refugees/displacement
NET versus FTC versus monitoring
n/r
PDS (DSM-IV)
n/r
n/r
Neuner et al. (2010)
Germany
32 (68.8%)
Refugees/displacement
NET versus TAU
n/r
PDS (DSM-IV)
n/r
n/r
(Continues)
VARKER ET AL.
Loss of
diagnosis
(n = 83)
|
N (Male %)
Trauma type
Intervention
Authora
Country
16 of 36
TABLE 1
(Continued)
Authora
Country
N (Male %)
Trauma type
Intervention
Treatment response (n = 98)
Loss of
diagnosis
(n = 83)
Remission and Recovery
(n = 28)
Treatment nonresponse and
worsening including relapse
(n = 17)
Nidich et al. (2018)
USA
203 (83.2%)
Military
PE versus TM versus PsychEdu
≥10-point reduction on CAPS
(DSM-IV) OR
≥10-point reduction on PCL-M
(DSM-IV) OR
≥10-point reduction on PHQ-9
(Clinically meaningful)
n/r
n/r
n/r
Nijdam et al. (2012)
Netherlands
140 (43.6%)
Mixed trauma
BEP versus EMDR
n/r
SI-PTSD
(DSM-IV)
n/r
n/r
Onder et al. (2006)
Turkey
103 (49.5%)
Natural disaster
FLX versus moclobemide versus TNP
≥50% reduction on CAPS (DSM-IV)
OR
Rating of 1 or 2 on CGI-S
n/r
n/r
n/r
Orang et al. (2018)
Iran
45 (0%)
IPV
NET versus TAU
RCI = 15 points (PSS-I, DSM-IV)
(Clinically meaningful)
PSS-I (DSM-IV)
n/r
n/r
Pacella et al. (2012)
USA
65 (63.1%)
Mixed trauma
PE versus Monitoring
Cutoff ≤ 20 points on HIV-related
PSS-I (DSM-IV) AND
Cutoff ≤ 20 points on non–HIVrelated PSS-I (DSM-IV) AND
Cutoff ≤ 16 points on CES-D
(Good end-state functioning)
PDS (DSM-IV)
n/r
n/r
Panahi et al. (2011)
Iran
70 (100%)
Military
SRT versus PBO
≥30% reduction on IES-R (DSM-IV)
AND
Rating of 1 or 2 on CGI-I
n/r
n/r
n/r
Paunovic et al. (2011)
Sweden
29 (41.4%)
Mixed trauma
Exposure inhibition Therapy* versus WL
n/r
Cutoff ≥ 44
points on CAPS
(DSM-IV) OR
Cutoff ≥ 39
points on CAPS
(DSM-IV) OR
Cutoff ≥ 27
points on CAPS
(DSM-IV)
n/r
n/r
VARKER ET AL.
TABLE 1
|
17 of 36
(Continues)
(Continued)
N (Male %)
Trauma type
Intervention
Treatment response (n = 98)
Loss of
diagnosis
(n = 83)
Remission and Recovery
(n = 28)
Treatment nonresponse and
worsening including relapse
(n = 17)
Popiel et al. (2015)
Poland
228 (n/r)
MVA
PE versus PRX versus PE + PRX
n/r
n/r
CAPS (DSM-IV) AND
Absence of the minimal
number of symptoms
required for a PTSD
diagnosis on PDS
(Remission)
> 1 SD increase in number
of PTSD symptoms (PDS,
DSM-IV)
(Relapse)
Powers et al. (2015)
USA
9 (11.1%)
n/r
PE versus PE + exercise
Cutoff ≤ 10 points on PSS-I
(DSM-IV)
(Good end-state functioning)
n/r
n/r
n/r
Rauch et al. (2015)
US
36 (91.7%)
Military
PE versus PCT
≥10-point reduction on CAPS
(DSM-IV)
(Clinically meaningful)
≥50% reduction on CAPS (DSM-IV)
CAPS (DSM-IV)
n/r
n/r
Rauch et al. (2018)
USA
223 (87%)
Military
SRT versus PE + PBO versus PE + SRT
≥50% reduction on CAPS
(DSM-IV-TR)
≥20-point reduction on CAPS (DSMIV-TR) OR
Cutoff ≤ 35 points on CAPS
(DSM-IV-TR)
(Clinically meaningful)
n/r
Cutoff ≤ 35 points on
CAPS (DSM-IV-TR)
(Remission)
n/r
Reger et al. (2016)
USA
162 (96.3%)
Military
PE versus VR-EXP versus WL
RCI = 1.65 points (CAPS, DSM-IV)
>2 SD reduction on CAPS (DSM-IV)
Cutoff = 52.78 points
(Clinically meaningful)
n/r
n/r
RCI (=1.65) changed
in direction of greater
dysfunction (CAPS,
DSM-IV)
(Worsening)
Resick et al. (2002)
USA
171 (0%)
Sexual assault
CPT versus PE versus MA
Cutoff ≤ 20 points on PSS (DSM-IV)
AND
Cutoff ≤ 10 points on BDI
(Good end-state functioning)
CAPS (DSM-IV)
n/r
n/r
Resick et al. (2008)
USA
150 (0%)
Mixed trauma
CPT versus CPT-C versus Written accounts
n/r
CAPS (DSM-IV)
n/r
n/r
VARKER ET AL.
(Continues)
|
Authora
Country
18 of 36
TABLE 1
(Continued)
Authora
Country
N (Male %)
Trauma type
Intervention
Treatment response (n = 98)
Loss of
diagnosis
(n = 83)
Remission and Recovery
(n = 28)
Treatment nonresponse and
worsening including relapse
(n = 17)
Resick et al. (2017)
USA
268 (91%)
Mixed trauma
CPT versus CPT group
n/r
PSS-I (DSM-IV)
n/r
n/r
Rothbaum et al. (2006)
USA
65 (35.4%)
Mixed trauma
PE + SRT versus SRT
>1 SD reduction on SIP (DSM-IV)
Cutoff < 14 points
(Excellent responders)
Cutoff ≥ 14 points
(Partial responders)
n/r
n/r
n/r
Roy et al. (2010)
USA
29 (89.7%)
Military
IE versus VR-EXP
>30% reduction on CAPS (DSM-IV)
n/r
n/r
n/r
Sack et al. (2016)
Germany
139 (36%)
Mixed trauma
EMDR versus EMDR hand moving versus
EMDR nonmoving hand
≥20-point reduction on CAPS
(DSM-IV)
(Clinically meaningful)
SCID-PTSD
assessment
(DSM-IV)
n/r
n/r
Sannibale et al. (2013)
Australia
62 (47%)
Mixed trauma
I-CBT versus alcohol support
Cutoff < 37 points on CAPS
(DSM-IV)
(Clinically meaningful)
CAPS (DSM-IV)
n/r
n/r
Schaal et al. (2009)
Rwanda
26 (38.5%)
Refugees/displacement
NET versus IPT
n/r
CAPS (DSM-IV)
n/r
n/r
Schacht et al. (2017)
USA
58 (21%)
Mixed trauma
PE versus PE with incentives
≥15-point reduction on CAPS
(DSM-IV)
(Clinically meaningful)
n/r
n/r
n/r
Schneier et al. (2012)
USA
37 (45.9%)
Terrorism
PE + PRX versus PE + PBO
Rating of 1 or 2 on CGI-C
n/r
Cutoff ≤ 20 points on
CAPS (DSM-IV) AND
Rating of 1 on CGI-C
(Remission)
n/r
Schneier et al. (2015)
USA
36 (36.1%)
Mixed trauma
SRT + PBO versus SRT + MRTZ
>30% reduction on CAPS (DSM-IV)
AND
Rating of 1 or 2 on CGI-I
n/r
Cutoff < 20 points on
CAPS (DSM-IV)
(Remission)
n/r
VARKER ET AL.
TABLE 1
|
19 of 36
(Continues)
(Continued)
N (Male %)
Trauma type
Intervention
Treatment response (n = 98)
Loss of
diagnosis
(n = 83)
Remission and Recovery
(n = 28)
Treatment nonresponse and
worsening including relapse
(n = 17)
Schnurr et al. (2007)
USA
284 (0%)
Mixed trauma
PE versus PCT
≥10-point reduction on CAPS
(DSM-IV)
CAPS (DSM-IV)
Cutoff < 20 points on
CAPS (DSM-IV)
(Remission)
n/r
Schnyder et al. (2011)
Switzerland
30 (53.3%)
Mixed trauma
BEP versus MA
≥1 SD reduction on CAPS (DSM-IV)
Cutoff = 18 points
CAPS (DSM-IV)
Cutoff < 20 points on
CAPS (DSM-IV)
(Remission)
n/r
Seo et al. (2010)
Korea
40 (30%)
Mixed trauma
PRX versus MRTZ
≥30% reduction on CAPS (DSM-IV)
n/r
n/r
n/r
Sloan et al. (2018)
USA
126 (52.4%)
Mixed trauma
CPT versus WET
RCI = 13 points (CAPS, DSM-V)
CAPS (DSM-V)
n/r
n/r
Stenmark et al. (2013)
Norway
81 (69.1%)
Refugees/displacement
NET versus TAU
>2 SD reduction on CAPS (DSM-IV)
Cutoff = n/r
(Clinically meaningful)
CAPS (DSM-IV)
n/r
n/r
Tarrier et al. (1999)
UK
72 (58%)
Mixed trauma
IE versus CT
Rating of 0 or 1 on CAPS Global
Severity (DSM-III-R) AND
Rating of 0 or 1 on CAPS Global
Improvement (DSM-III-R)
(Clinically meaningful)
CAPS
(DSM-III-R)
n/r
n/r
Ter Heide et al. (2011)
Netherlands
20 (60%)
Refugees/displacement
EMDR versus stabilization
n/r
SCID-I
(DSM-IV)
n/r
n/r
Ter Heide et al. (2016)
Netherlands
72 (72.2%)
Refugees/displacement
EMDR versus stabilization
≥10-point reduction on CAPS
(DSM-IV-TR)
(Clinically meaningful)
CAPS
(DSM-IV-TR)
n/r
≥ 10-point increase on CAPS
(DSM-IV-TR)
(Worsening)
Triffleman et al. (2000)
USA
19 (47.4%)
n/r
I-CBT versus 12-step facilitation
n/r
CAPS (DSM-IV)
n/r
n/r
Tucker et al. (2001)
USA and Canada
323 (34.2%)
Mixed trauma
PRX versus PBO
Rating of 1 or 2 on CGI-I
n/r
Cutoff < 20 points on
CAPS (DSM-IV)
(Remission)
n/r
VARKER ET AL.
(Continues)
|
Authora
Country
20 of 36
TABLE 1
(Continued)
N (Male %)
Trauma type
Intervention
Treatment response (n = 98)
Tuerk et al. (2018)
USA
26 (100%)
Military
PE + PBO versus PE + yohimbine HCl
>1 SD reduction on PCL-M
(DSM-IV-TR)
Cutoff = n/r
Van Den Berg et al.
(2015)
Netherlands
155 (45.8%)
Mixed trauma
PE versus EMDR versus WL
van Denderen et al.
(2018)
Netherlands
Remission and Recovery
(n = 28)
Treatment nonresponse and
worsening including relapse
(n = 17)
CAPS
(DSM-IV-TR)
n/r
n/r
n/r
CAPS
(DSM-IV-TR)
Cutoff < 20 points on
CAPS (DSM-IV-TR)
(Remission)
n/r
85 (26%)
Homicide bereavement
EMDR + CBT versus CBT + EMDR
versus WL (EMDR + CBT) versus WL
(CBT + EMDR)
>2 SD reduction on IES (version not
reported)
Cutoff = 23 points
(Clinically meaningful)
n/r
n/r
n/r
Van der Kolk et al.
(2007)
USA
88 (17%)
Mixed trauma
EMDR versus FLX versus PBO
n/r
CAPS (DSM-IV)
Cutoff < 20 points on
CAPS (DSM-IV)
(Remission)
n/r
Wells et al. (2015)
UK
32 (62.5%)
Mixed trauma
PE versus metacognitive therapy versus WL
RCI = 10 points (IES, DSM-IV)
>2 SD reduction (IES, DSM-IV)
Cutoff ≤ 32 points
(Clinically meaningful)
SCID
(DSM-IV-R)
Achieving reliable
change and clinically
meaningful change
(Recovery)
RCI (= 10) changed in
direction of greater
dysfunction (IES, DSM-IV)
(Worsening)
Yehuda et al. (2014)
USA
52 (89.2%)
Military
PE versus MA
n/r
CAPS (DSM-IV)
n/r
n/r
Yehuda et al. (2015)
USA
24 (n/r)
Mixed trauma
PE + PBO versus PE + hydrocortisone
n/r
CAPS (DSM-IV)
n/r
n/r
Yuen et al. (2015)
USA
52 (98.1%)
Military
PE versus PE telehealth
n/r
CAPS (DSM-IV)
n/r
n/r
Ziemba et al. (2014)
USA
18 (90%)
Military
CBT versus CBT telehealth
≥15-point reduction on CAPS
(DSM-IV-TR)
(Clinically meaningful)
n/r
n/r
n/r
Authora
Country
Loss of
diagnosis
(n = 83)
VARKER ET AL.
TABLE 1
|
21 of 36
(Continues)
(Continued)
N (Male %)
Trauma type
Intervention
Treatment response (n = 98)
Loss of
diagnosis
(n = 83)
Remission and Recovery
(n = 28)
Treatment nonresponse and
worsening including relapse
(n = 17)
Zoellner et al. (1999)
USA
95 (0%)
Mixed trauma
CBT versus WL
Cutoff ≤ 20 points PSS-I (DSM-III-R)
AND
Cutoff ≤ 40 points on STAI-S AND
Cutoff ≤ 10 points on BDI
(Good end-state functioning)
n/r
n/r
n/r
Zoellner et al. (2018)
USA
200 (24.5%)
Mixed trauma
PE versus SRT
Cutoff < 24 points on PSS-I
(DSM-IV) AND
Rating of < 4 on CGI-I
PSS-I (DSM-IV)
n/r
n/r
Zohar et al. (2002)
Israel
42 (88.2%)
Military
SRT versus PBO
≥30% reduction on CAPS (DSMIII-R) OR
Rating of 1 or 2 on CGI-I OR
Both of the above
(Clinically meaningful)
n/r
n/r
n/r
|
Authora
Country
22 of 36
TABLE 1
Abbreviations: AC, addictive counseling; AMI, amitriptyline; A-TEAS, active transcutaneous electrical acupoint stimulation; BAI, Beck Anxiety Inventory; BA-TE, behavioral activation and therapeutic exposure; BDI,
Beck Depression Inventory; BEP, brief eclectic psychotherapy; CAPS, Clinician-Administered PTSD Scale; CBT (TF) = trauma-focused cognitive behavioral therapy; CBT, cognitive behavioral therapy; CES-D, Center
for Epidemiological Studies—Depression Scale; CGI-C, Clinical Global Impressions Scale—Change; CGI-I, Clinical Global Impressions Scale—Improvement; CGI-S, Clinical Global Impressions Scale—Severity; CIDI,
Composite International Diagnostic Interview; COPE, Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure; CPA, childhood physical abuse; CPT (smart) = CPT + cognitive rehabilitation
strategies; CPT, cognitive processing therapy; CPT-C, cognitive processing therapy—cognitive therapy only; CR, cognitive restructuring; CSA, childhood sexual abuse; CT, cognitive therapy; DBT, dialectical behavior
therapy; DCS, D-cycloserine; DET, dialogical exposure therapy; DSM, Diagnostic and Statistical Manual of Mental Disorders; EFT, emotional freedom techniques; EMDR, eye movement desensitization and reprocessing;
FLX, fluoxetine; FTC, flexible trauma counseling; GHQ, General Health Questionnaire; HAMD, Hamilton Rating Scale for Depression; HIV, human immunodeficiency virus; HLS, Health Information Control; HTQ, Harvard
Trauma Questionnaire; I-CBT, integrated cognitive behavioral therapy; ICD-10, International Classification of Diseases—10th Revision; IE, imaginal exposure; IES, Impact of Event Scale; IES-R, Impact of Event Scale—
Revised; IPT, interpersonal psychotherapy; IPV, intimate partner violence; IR, imagery rescripting; IRT, imagery rehearsal therapy; M.I.N.I., The Mini-International Neuropsychiatric Interview; MA, minimal attention; MCC,
minimal contact control; M-CPT, modified cognitive processing therapy; MET-PTSD, Trauma-Focused Motivational Enhancement Session; M-PE, Modified PE; MPSS, Modified Posttraumatic Stress Disorder Symptom Scale;
MPSS-SR, Modified Posttraumatic Stress Disorder Symptom Scale—Self-report; MRTZ, mirtazapine; MVA, motor vehicle accident; n/r, not reported; NET, narrative exposure therapy; NLTX, naltrexone; PBO, Placebo; PCL,
PTSD Checklist; PCL-C, PTSD Checklist—Civilian; PCL-M, PTSD Checklist—Military; PCL-S, PTSD Checklist—Stressor-Specific; PCT, present-centered therapy; PDS, Posttraumatic Diagnostic Scale; PDS-I, Posttraumatic
Diagnostic Scale—Interview; PE, prolonged exposure; PHQ, Patient Health Questionnaire; PRX, paroxetine; PSS, Posttraumatic Stress Disorder Symptom Scale; PSS-I, Posttraumatic Stress Disorder Symptom Scale—
Interview; PSS-SR, Posttraumatic Stress Disorder Symptom Scale—Self-Report; PsychEdu, psychoeducation; PTSD, posttraumatic stress disorder; RCI, Reliable Change Index; RST, Rogerian supportive therapy; RT, relaxation
therapy; rTMS, repetitive transcranial magnetic stimulation; SC, supportive counseling; SCID, Structured Clinical Interview for DSM-IV Axis I Disorders; SD, standard deviation; SHB, Self-help Booklet; SIP, Structured
Interview for PTSD; SI-PTSD, Structured Interview for PTSD; SIT, stress inoculation training; Skills, emotion regulation skills; SMDT, symptom-monitoring delayed treatment; SPT, supportive psychotherapy; SRT, sertraline;
SS, safety seeking; STAIR, Skills Training in Affective and Interpersonal Regulation; STAI–S, State-Trait Anxiety Inventory—State subscale; S-TEAS, simulated transcutaneous electrical acupoint stimulation; TARGET,
Trauma Affect Regulation: Guide for Education and Therapy; TAU, treatment as usual; TM, transcendental meditation; TMT, trauma management therapy; TNP, tianeptine; TOP-8, Treatment Outcome PTSD Rating Scale;
VLFX, venlafaxine; VR-EXP, virtual reality exposure; WET, written exposure therapy; WL, wait list.
*Exposure intervention based on PE.
a
Reference list can be requested from lead author.
VARKER ET AL.
|
VARKER ET AL.
identified their population as chronic (n = 51, 35.7%; commonly defined as PTSD diagnosis longer than 6 months, but
in some instances, as short as 3 months), while a small number involved a treatment-resistant population (n = 2, 0.7%).
3.2
|
Interventions
Two thirds of trials involved first-line psychological interventions (n = 105, 73.4%), while a smaller proportion involved first-line pharmacological (n = 23, 16.1%)
or combined interventions (n = 15, 10.5%). Of the psychological trials, prolonged exposure (n = 41, 39%) and
cognitive behavior therapy (n = 22, 21%) were the most
common interventions. Of the pharmacological trials, the
most common interventions were sertraline (n = 9, 39.1%)
and fluoxetine (n = 7, 30.4%). The majority of the chronic
PTSD trials (n = 33, 64.7%) investigated the efficacy of
psychological interventions, followed by pharmacological
interventions (n = 15, 29.4%) and combined interventions
(n = 3, 5.9%).
3.3 | Operationalization of response
to treatment
Figure 2 represents the synthesized categories and subcategories of response to treatment definitions. From the 143
trials included in this review, 226 definitions were extracted,
matching the following five categories: treatment response
(n = 181), remission (n = 23), recovery (n = 5), treatment
nonresponse (n = 5), and worsening (n = 12). There were
no trials that defined all five categories, but one trial defined
four categories (Wells, Walton, Lovell, & Proctor, 2015).
Approximately three-quarters of trials (n = 106, 74.1%) only
defined treatment response (including loss of diagnosis).
Nineteen trials (13.3%) differentiated between treatment response and remission, four trials (2.8%) between treatment
response and recovery, and 15 trials (10.5%) between treatment response and nonresponse.
The author-defined definitions used by each trial included
in the qualitative synthesis are presented in Table 1.
3.4
|
Treatment response definitions
In the treatment response category, 79 trials (80.1%) defined
response using a reduction of PTSD symptom severity, 12
trials (12.2%) used a reduction of PTSD symptom severity
plus improvement in functioning, and seven trials (7.1%) assessed improvement in functioning only. Further information
on how these reductions or improvements were defined is
presented below.
3.4.1
|
23 of 36
Reduction of PTSD symptom severity
The majority of trials based their definition(s) of treatment response on the reduction of PTSD symptom severity
(n = 79) in terms of: (a) a minimum score reduction on a clinician-rated or self-report PTSD measure (“minimum score
reduction,” n = 20); (b) a cutoff score on a clinician-rated
or self-report PTSD measure, using a predefined statistical
formula (“cutoff score derived from a predefined statistical
formula,” n = 17); (c) a minimum percentage reduction on
a clinician-rated or self-report PTSD measure scores (“minimum percentage reduction,” n = 10); or (d) meeting a predefined cutoff score for a clinician-rated or self-report PTSD
measure (“cutoff score,” n = 10). These four subcategories
are further elaborated below with examples.
Minimum score reduction (clinician-rated)
The Clinician-Administered PTSD Scale (CAPS) was the
only clinician-rated measure used, with trials requiring a
minimum score reduction of either 10 points (n = 8), 12
points (n = 2), 15 points (n = 9), or 20 points (n = 1).
Cutoff score derived from a predefined statistical formula
(clinician-rated)
Jacobson and Truax's (1991) formula was predominately used
for definitions using a cutoff score derived from a statistical
formula. The formula is used to determine whether a change in
an individual's score is clinically significant. An individual is
considered to have made clinically significant improvement if
their post-treatment scores move outside the range of the population of those with a disorder, or within the range of scores of
the population with no disorder (Jacobson & Truax, 1991).
Most frequently, a 2 standard deviation reduction between
pre- and post-treatment scores on a clinician-rated PTSD
measure was used to confirm change (n = 8). Formulas using
reductions of 1 or 0.5 standard deviation (n = 3) were also
used to identify minimal clinically meaningful differences.
These less conservative formulas were chiefly confined
to noninferiority trials. Second, the formula can be used to
determine whether the magnitude of change is statistically
reliable, which uses the Reliable Change Index (RCI). The
RCI can be calculated by dividing the difference between
pretreatment and post-treatment scores by the standard
error of the difference between the two scores (Jacobson
& Truax, 1991). Twelve trials used RCI definitions, with
reliable change scores ranging from 11.09 to 17.70 points
on CAPS (CAPS-V = 13.0; CAPS-IV = 11.09; and CAPSIV-TR = 12.0 and 17.7), and from 7 to 15 on the PTSD
Symptom Scale—Interview (PSS-I).
Minimum percentage reduction (clinician-rated)
Of the ten trials that defined treatment response as a percentage reduction in PTSD symptom severity, the majority used
24 of 36
|
VARKER ET AL.
Trials (n = 143) containing 226 definitions
Treatment response
defined with four
methods of assessment
(n = 181)
Remission defined using a
pre-defined cut-off score
on a clinician-rated
assessment
(n = 23)
Recovery defined with a
pre-defined cut-off score
on a clinician-rated
assessment or based on a
statistical derived formula
on a clinician or self-rated
assessment
(n = 5)
Treatment non-response
defined as not meeting a
priori treatment response
definition, retaining
PTSD diagnosis or
severity increase on a
clinician-rated functional
assessment
(n = 5)
Worsening including
relapse defined as
severity increase (score or
statistically derived
formula) on a clinicianrated PTSD or functional
assessment
(n = 12)
PTSD symptom severity reduction defined as a score or percentage reduction, cut-off score or statistically
derived formula on clinician-rated or self-rated PTSD assessments (n = 79) in terms of:
(1) a minimum score reduction (n = 20)
(2) a cut-off score derived from a predefined statistical formula (n = 17)
(3) a minimum percentage reduction (n = 10)
(4) meeting a pre-defined cut-off score (n = 10)
PTSD severity reduction plus functioning improvement defined as a score or percentage reduction, cutoff score or statistically derived formula on clinician-rated or self-rated PTSD and functional assessment
(n = 12)
Functioning improvement defined as cut-off score on functional assessments (n = 7)
Loss of diagnosis defined as no longer meeting the diagnostic criteria on a clinican-rated assessment
(n = 83)
FIGURE 2
Definitions of treatment response and nonresponse used within the synthesized trials included in the review
a 30% reduction on CAPS-IV (n = 6) to indicate significant
improvement. Two studies examining pharmacological interventions (Martenyi, Brown, & Caldwell, 2007; Martenyi,
Brown, Zhang, Prakash, & Koke, 2002) used a 50% reduction to indicate treatment response.
Cutoff scores (clinician-rated)
Ten trials used a predefined cutoff score on a clinician-rated
measure. The majority of these trials operationalized treatment
response as a score of ≤20 on either the CAPS-IV or PSS-I.
Weathers, Keane, and Davidson (2001) suggest that a score of
≤19 on the CAPS-IV indicates that a patient is asymptomatic
or has few symptoms, whereas Foa (1995; Foa et al., 1999)
suggests that a score of ≤20 on the PSS-I and PSS-Self-Report
(PSS-SR) indicates “good end-state functioning,” which is
presumably synonymous with remission or recovery.
Self-rated outcomes
In comparison with definitions of treatment response derived from clinician-rated assessments, definitions based on
self-report evaluations were used less frequently and varied
widely. For example, out of 26 trials that used self-report
assessments when defining treatment response, seven included definitions based on threshold score reductions (5.0
and 8.8 points on the PTSD Checklist [PCL]; and 20 points
on the Posttraumatic Diagnostic Scale [PDS], PSS-SR, or
the Modified Posttraumatic Stress Disorder Symptom Scale
[MPSS-SR]). Four trials used threshold percentage reductions (30% on the Impact of Event Scale—Revised [IES];
50% on PDS; or 70% on PSS-SR), and two trials used cutoff scores (44 points or 50 points on the PCL). Nine studies
used sample mean cutoff scores to define treatment response.
These mainly incorporated a 2 standard deviation reduction
on IES scores, and therefore, there was a range of cutoffs
used among the trials to indicate clinically significant change.
Only one trial used a RCI of a 10-point decrease on the IES to
indicate treatment response (Wells et al., 2015).
3.4.2 | Definitions incorporating a reduction
in PTSD symptom severity plus improvement
in function
The most comprehensive definitions of treatment response
(n = 12) incorporated a combination of clinician-rated or
self-report PTSD symptom severity outcomes and functional
outcomes. The most common of these definitions combined
a 30% or greater reduction on the CAPS with a Clinical
Global Impression of Improvement (CGI-I) rating of 1 or 2
(n = 8). Two other trials used the clinician-rated PSS-I or the
|
VARKER ET AL.
self-report IES/IES-Revised in conjunction with either the
CGI-I or the General Health Questionnaire (GHQ) global improvement scale to define treatment response (Marks, Lovell,
Noshirvani, Livanou, & Thrasher, 1998; Zohar et al., 2002).
One trial provided a definition, which included both the assessor's CAPS global severity rating and the participants'
own CAPS global improvement rating (Tarrier et al., 1999),
and another provided a definition, which included both clinician-rated PTSD outcomes (CAPS 2) and the GHQ global
improvement scale (Marks et al., 1998).
3.4.3 | Defining treatment response as
improvement in function only
PTSD treatment response was also defined in terms of only
functional improvement in seven trials. Most trials used the
CGI-I (n = 5), and one used the Duke Improvement Scale
(n = 1). In all of these trials, treatment responders were categorized using a global improvement score of 1 (very much
improved) or 2 (much improved), or an improved rating
of two or more points (n = 1). Six of the seven trials that
used functional improvement to measure treatment response
examined pharmacological interventions, including fluoxetine (Connor et al., 1999; Hertzberg, Feldman, Beckham,
Kudler, & Davidson, 2000) and paroxetine (Marshall, Beebe,
Oldham, & Zaninelli, 2001; Marshall et al., 2007; Schneier
et al., 2012; Tucker et al., 2001).
3.4.4 | Treatment response as
loss of diagnosis
Response to treatment was operationalized as loss of diagnosis in 83 (58%) trials. The most common of these definitions were based on the CAPS diagnostic criteria (n = 54).
A further twenty-three trials defined response as loss of diagnosis based on clinician-rated assessments other than the
CAPS—most commonly the PDS or the Structured Clinical
Interview for DSM-IV (SCID). Only three trials went beyond
the diagnostic criteria by pairing loss of diagnosis with a cutoff score in the definition (i.e., score of <45 or <50 on the
CAPS; Monson et al., 2006; Schnurr et al., 2007; Schnyder,
Müller, Maercker, & Wittmann, 2011). Six studies defined
loss of diagnosis using self-report assessment cutoff scores
(i.e., <2.5 on the Harvard Trauma Questionnaire [HTQ], <14
on the PDS, and <20 on the PSS-SR).
3.5
|
Remission definitions
Response to treatment was operationalized and labeled as
remission in 23 trials. In contrast to other definitions, there
25 of 36
was more consistency in the definition of remission with
16 trials (69.6%) using a score of ≤20 points on the CAPS
as the cutoff. Two trials used less stringent CAPS cutoff
scores to define remission, namely ≤35 points (Rauch
et al., 2018) or ≤50 points (Back et al., 2019), while Ehlers
et al. (2014) used both a 20-point cutoff score on the CAPS
and a score of <11 on the PDS in their trial. Three studies
(Butollo, Karl, König, & Rosner, 2016; Harned, Korslund,
& Linehan, 2014; Popiel, Zawadzki, Pragłowska, &
Teichman, 2015) defined treatment response as “remission”
and described remission as not meeting PTSD criteria in the
last month. However, they did not provide details of which
cutoff scores were used. Global functioning was only considered in the definition of remission in one trial. Schneier
et al. (2012) defined treatment response as ≤20 points on
the CAPS and a rating of 1 (very much improved) on the
CGI-Change.
3.6
|
Recovery definitions
Five trials offered definitions of recovery, with two trials using the Jacobson and Truax’s (1991) reliable change
formula to identify reliably and clinically significant indices of change to indicate recovery. Two trials identified
recovery as change on a clinician-rated assessment (i.e.,
>10.5-point reduction and a cutoff score of ≤14.9 in PSSI; Feske, 2008; Harned et al., 2014), and one trial used
a self-rated assessment (i.e., 10-point reduction and cutoff score of ≤32 on IES; Wells et al., 2015). The fourth
trial calculated clinically significant differences based on
the RCI (8-point reduction on PSS-I) to differentiate between improved, recovered, not reliably changed, and deteriorated (Langkaas et al., 2017). The fifth trial offered
a definition of recovery, which was a score of ≤20 points
on the PSS-SR (Arntz, Tiesema, & Kindt, 2007). It should
be noted that there was some overlap in the way in which
recovery and remission were defined. For example, three
studies described remission as not meeting PTSD criteria
in the last month (cutoff score details were not provided),
while one study defined recovery as having a score of ≤20
points on the PSS-SR.
3.7
|
Treatment nonresponse definitions
Nonresponse was defined in five trials as failure to meet
the treatment response definition (Back, Brady, Sonne, &
Verduin, 2006; Blanchard et al., 2003; Chung et al., 2004;
Connor et al., 1999) or as a deterioration in function only
(Duke Improvement Scale > 2; Hertzberg et al., 2000).
No studies provided operational definitions of treatment
resistance.
26 of 36
|
VARKER ET AL.
3.8 | Worsening (including relapse)
definitions
Worsening was defined in 10 trials primarily as a reliable
change in the direction of greater dysfunction, based on the
Jacobson and Truax (1991) formula (RCI ranged between
1.65 and 10), as an increase in severity of symptoms from
baseline to post-treatment on a clinician-rated assessment
(e.g., PDS > 6.15; CAPS-IV > 10 points), or as a decline in
function only (≥3 points on CGI-I). Finally, symptom exacerbation or relapse was defined in two trials as an increase
in symptom severity scores, with either an increase in one
standard deviation on the PDS (Popiel et al., 2015) or a score
increase indicative of decline in function on the CGI (i.e.,
a score ≥ 4 at post-treatment or a ≥ 2-point increase on the
CGI relative to improvement status at week 24; Davidson
et al., 2005).
4
|
D IS C U SS ION
As far as the present authors are aware, this is the first systematic review to comprehensively consider how response
and nonresponse to PTSD treatment have been operationalized in PTSD treatment trials. It was concerning to find that
a substantial number of eligible research trials (n = 49) investigating the efficacy of PTSD interventions did not operationalize treatment response (and therefore were excluded
from the qualitative synthesis). As trial reporting standards
have been introduced and become commonplace, we have
seen an improvement in the utilization of the operational
definitions over time. Nevertheless, our findings show that
of trials published within the last 10 years, more than a
quarter still failed to operationalize treatment response or
nonresponse. Trials that did not operationalize treatment
response typically used statistical tests to show betweengroup differences, and concluded that there was significant benefit, decreases in PTSD symptoms, or differences
in rates of a PTSD diagnosis. Some trials also stated that
there was a greater treatment response for one group over
another. However, none of these trials paired this wording
with definitions of numerical scores or changes in diagnosis status on validated measures to operationalize treatment
response. This represents a major methodological concern
and undermines efforts to examine the comparative efficacy of treatments across trials when these terms are not
defined. It is essential that future studies of PTSD treatment include these important definitions to help determine
the effectiveness of the treatments.
In this systematic review, the most popular categories
used to describe treatment response were as follows: treatment response, remission, recovery, treatment nonresponse,
and worsening. The review identified a preference across
PTSD trials to operationalize treatment response using either
a predetermined percentage or score reduction in symptom
severity, or a cutoff symptom score on a clinician-rated assessment. Several concerns arise from these approaches.
First, the validity of the method by which these definitions have been formulated is dubious. For example, with
one exception (i.e., CAPS 10-point benchmark; Schnurr &
Lunney, 2016) the nominated cutoff scores reported across
trials were not empirically derived, instead appearing to have
been arbitrarily chosen. The findings highlight a need to: (a)
empirically identify and test the validity of different cutoff
scores for different assessment tools (e.g., CAPS versus PSSI) and different versions of the tools (e.g., CAPS-IV versus
CAPS-5), ensuring all are anchored to some form of discernible “difference” in the clinical picture; and (b) empirically
differentiate between different cutoff scores relating to different categories of treatment response.
A second concern relates to the fact that definitions based
on symptom severity reductions do not take into consideration baseline symptom severity (Yehuda & Hoge, 2016).
Using these methods, a person with severe PTSD may
achieve symptom improvement, but still exhibit significant
levels of symptomatology and functional impairment or retain the clinical diagnosis. A 10-point reduction on CAPS,
for example, is unlikely to be deemed a significant clinical
treatment response for clients with severe PTSD symptomatology scoring 60 or 70 on the CAPS at baseline. As such,
the individual finds themselves in the confused position of
being both “a treatment success” but continuing to be heavily burdened by ill health and associated disability. Thus,
incorporating a symptoms' cutoff in addition to amount
of symptom improvement could be a useful way to define
treatment response to avoid this problem. Furthermore, a
better understanding of residual symptoms may help further clarify which symptoms continue to affect quality of
life and predict the likelihood of relapse or other long-term
outcomes (Larsen et al., 2019). They also can inform which
treatment strategies are most helpful and consequently lead
to a better understanding of the mechanisms of change and
longitudinal course of PTSD. This would not only allow for
improvements to treatment response definitions, but also
may assist in improving treatment outcomes through augmented treatments specifically targeting residual symptoms
(Metcalf et al., 2019).
Consistent with the views expressed previously (e.g.,
Schnurr, Hayes, Lunney, McFall, & Uddo, 2006; Schnurr &
Lunney, 2016; Sippel et al., 2018), it is somewhat concerning
that the most common PTSD treatment response is defined
in terms of symptom severity scores or percentage reductions alone, in the absence of other meaningful treatment
outcomes. Yehuda and Hoge (2016) commented on the need
to expand treatment outcomes beyond symptom reductions
and incorporate other meaningful goals related to physical
|
VARKER ET AL.
health, well-being, interpersonal connections, and functioning in vocational or social settings. A similar sentiment has
been supported by Schnurr and Lunney (2016), who conceptualized meaningful improvement to reflect real-world quality of life impacts (i.e., improvements in social, occupational,
emotional, physical and social functioning, and life satisfaction), rather than the degree of change in PTSD symptom
severity, as this has been found to not necessarily result in
improvements across quality of life domains. There is evidence that improvements in functioning and quality of life
do not necessarily occur at the same rate or trajectory as the
amelioration of symptoms (Keller, 2003). Such outcomes are
often recognized by patients as more important and meaningful than symptom relief (Cuijpers, 2019). It is our view
that definitions of treatment response should systematically
incorporate assessments of function. However, in the absence of a gold-standard assessment of functionality (Lam,
Parikh, Michalak, Dewa, & Kennedy, 2015), an appropriate
tool must be selected depending on the specific research
question, and taking into consideration the patient-reported
outcomes.
Ultimately, the treatment goal for any physical or mental health condition should be remission and finally recovery, or in simple terms, the absence of ill health and
a return to pre-illness functioning (Crosby, Kolotkin, &
Williams, 2003). In the current review, remission was consistently operationalized as achieving a score of 20 points or
less on the CAPS. However, the remission definitions used
in trials did not specify how long symptoms must be absent
for across a specific time period, which is problematic if
distinction is to be drawn between loss of diagnosis and remission. Furthermore, in some trials, remission and recovery referred to unique concepts, while in others, the terms
were used interchangeably.
There was little discussion in reviewed trials of how treatment nonresponse and worsening are determined. The few
studies that provided a definition commonly defined it as a
deterioration in symptom severity, or as not achieving the
definition of treatment response. This reflects the general
lack of discussion around the quality of negative outcomes in
PTSD clinical trials (Yehuda & Hoge, 2016). Increased focus
on the issue of treatment nonresponse is recommended given
that just as the quality of treatment response varies between
groups and individuals, there is equal variability between
groups and individuals in the quality of nonresponse (e.g.,
partial response versus no change versus worsening following treatment). This in turn will guide the personalization of
treatment, and may also suggest a need for new and novel
treatment approaches (Sippel et al., 2018).
Critically, failure to reach agreed-upon and accepted
definitions of treatment response and nonresponse is not
without consequences, with the greatest real-world impact experienced in clinical practice. In this context,
27 of 36
debate and delay in determining treatment response and
when or when not to intervene undermines aspirations to
assertively intervene in a timely fashion when a first-line
treatment fails (i.e., secondary prevention). This, in turn,
unnecessarily exposes treatment seekers to risks of complications and comorbidity associated with treatment delay
(Wang et al., 2005) and significant burden associated with
the duration of untreated illness (McFarlane, 2019). Poorly
specified outcomes are also problematic because they can
lead to distortion of the true efficacy of interventions. Our
recommendation is that the CONSORT reporting guidelines for research trials include a requirement for clearly
defined and operationalized treatment outcomes that address the quality of treatment response and, as importantly,
treatment nonresponse.
4.1 | Operational definitions for
consideration
To move the trauma field forward, it is essential that there
are clearly defined and operationalized treatment response
categories. One way of agreeing-upon definitions for these
terms is to use a consensus-driven approach. Based on our
findings, we propose a set of consensus-driven operational
definitions (and depicted in Figure 3).
• Treatment response as measured on a clinician- and
self-rated scale is a reduction in an individual's baseline
symptomatology of ≥30%–50%. On CAPS, a clinically
meaningful response is indicated by a minimum score reduction of ≥15 points. A more rigorous form of treatment
response should also include a range of functional and
quality of life outcomes (e.g., interpersonal, social and occupational functioning, coping skills) and other indicators
of a “good end-state function” (e.g., depression and anxiety symptoms; Cuijpers, 2019; Yehuda & Hoge, 2016).
Inclusion of functional and quality of life outcomes in
research will help to ensure that treatment outcomes that
are clinically meaningful for the patient, and in clinical settings, will inform treatment decisions by patients
and providers (Stefanovics, Rosenheck, Jones, Huang, &
Krystal, 2018).
• Remission is defined as obtaining a score of ≤20 points on
the CAPS.
• Recovery is defined as maintaining a score of ≤20 points
on the CAPS at a time point of at least 6 months after treatment completion.
• Treatment nonresponse definitions should make the distinction between nonresponse, worsening, and treatment resistance. Nonresponse should be defined as failure to meet
the treatment response criteria, while worsening should
be differentiated from temporary symptom exacerbation
28 of 36
|
VARKER ET AL.
F I G U R E 3 Operational definitions
of treatment response and nonresponse
categories proposed based on the findings of
the review
(Foa, Zoellner, Feeny, Hembree, & Alvarez-Conrad, 2002)
and defined as persistent deterioration of symptoms. We
suggest that the field further investigates whether there is
a cutoff score that best represents worsening. This should
also take into account issues such as reduction in function and quality of life or increases in disability. Finally,
treatment resistance should be defined as lack of clinically
meaningful improvement despite provision of adequate
treatment (Sippel et al., 2018). Sippel et al. (2018) propose
a staged model to guide research and clinical management.
Specifically, Stage 1 treatment-resistant PTSD should be
defined as nonresponse to two evidence-based treatments
for PTSD, each delivered with high fidelity and at an effective dose. Stage 2 treatment-resistant PTSD is defined as
nonresponse to at least three evidence-based treatments.
Operationalization of these constructs will also help
to facilitate the development of clinical algorithms to
guide decision-making and treatment planning (Forbes
et al., 2019). For example, an algorithm for treatment-resistant PTSD has been developed (Dunlop, Kaye, Youngner,
& Rothbaum, 2014), which focuses on treatments with
proven efficacy that the patient has failed to respond to, to
determine whether the patient is treatment-resistant. This
work needs to be extended and built upon with high-quality
trials to test the utility of the proposed models. No algorithms currently exist to guide decision-making and treatment planning for those who are treatment-resistant and
experience nonresponse or worsening, representing a major
shortcoming for the PTSD field.
|
4.2
Strengths and limitations
A strength of this review was the inclusion of a large number of
trials providing treatment response and nonresponse definitions
for both psychological and pharmacological interventions for
PTSD. Limitations of the review include restricting the inclusion to interventions with strong recommendations from PTSD
guidelines and restricting the review to RCT methodologies.
5
|
CONCLUSION
This review identified significant diversity in the definitions of treatment response and nonresponse. It is clear
that the field of PTSD treatment is in need of a shared understanding of these concepts to increase agreement and
communication among clinicians and researchers. The next
step required is for researchers to test our proposed definitions to empirically validate them. Standardizing operational definitions of treatment response and nonresponse is
essential for the interpretation of research findings, their
translation into clinical practice, and improving comparability and generalization.
ACKNOWLEDGMENTS
This work was supported by Centenary of Anzac Centre, a
Department of Veterans' Affairs funded initiative of Phoenix
Australia. Thank you to Dr Olivia Metcalf for her assistance
with reviewing the final manuscript, and Ms Courtney Bowd for
her assistance in retrieving the articles included in this review.
VARKER ET AL.
ENDNOTE
1
h t t p : / / w w w. c r d . yo rk . a c . u k / P RO S P E RO / d i s p l ay _ r e c o r d .
php?ID=CRD42019119670.
R E F E R E NC E S
Acarturk, C., Konuk, E., Cetinkaya, M., Senay, I., Sijbrandij, M.,
Cuijpers, P., & Aker, T. (2015). EMDR for Syrian refugees with
posttraumatic stress disorder symptoms: Results of a pilot randomized controlled trial. European Journal of Psychotraumatology,
6(1), 27414. https://doi.org/10.3402/ejpt.v6.27414
Acarturk, C., Konuk, E., Cetinkaya, M., Senay, I., Sijbrandij, M., Gulen,
B., & Cuijpers, P. (2016). The efficacy of eye movement desensitization and reprocessing for post-traumatic stress disorder and
depression among Syrian refugees: Results of a randomized controlled trial. Psychological Medicine, 46(12), 2583–2593. https://
doi.org/10.1017/S0033291716001070
Acierno, R., Gros, D. F., Ruggiero, K. J., Hernandez-Tejada, M. A.,
Knapp, R. G., Lejuez, C. W., … Tuerk, P. W. (2016). Behavioral activation and therapeutic exposure for posttraumatic stress disorder:
A noninferiority trial of treatment delivered in person versus homebased telehealth. Depression and Anxiety, 33(5), 415–423. https://
doi.org/10.1002/da.22476
Acierno, R., Knapp, R., Tuerk, P., Gilmore, A. K., Lejuez, C., Ruggiero,
K., … Foa, E. B. (2017). A non-inferiority trial of Prolonged
Exposure for posttraumatic stress disorder: In person versus homebased telehealth. Behaviour Research and Therapy, 89, 57–65.
https://doi.org/10.1016/j.brat.2016.11.009
American Psychiatric Association (2013). Diagnostic and statistical
manual of mental disorders (DSM-5®). American Psychiatric Pub
Arntz, A., Tiesema, M., & Kindt, M. (2007). Treatment of PTSD: A comparison of imaginal exposure with and without imagery rescripting.
Journal of Behavior Therapy and Experimental Psychiatry, 38(4),
345–370. https://doi.org/10.1016/j.jbtep.2007.10.006
Asukai, N., Saito, A., Tsuruta, N., Kishimoto, J., & Nishikawa, T.
(2010). Efficacy of exposure therapy for Japanese patients with
posttraumatic stress disorder due to mixed traumatic events: A randomized controlled study. Journal of Traumatic Stress, 23(6), 744–
750. https://doi.org/10.1002/jts.20589
Back, S. E., Brady, K. T., Sonne, S. C., & Verduin, M. L. (2006).
Symptom improvement in co-occurring PTSD and alcohol dependence. The Journal of Nervous and Mental Disease, 194(9), 690–
696. https://doi.org/10.1097/01.nmd.0000235794.12794.8a
Back, S. E., Killeen, T., Badour, C. L., Flanagan, J. C., Allan, N. P., Ana,
E. S., … Brady, K. T. (2019). Concurrent treatment of substance
use disorders and PTSD using prolonged exposure: A randomized
clinical trial in military veterans. Addictive Behaviors, 90, 369–377.
https://doi.org/10.1016/j.addbeh.2018.11.032
Beidel, D. C., Frueh, B. C., Uhde, T. W., Wong, N., & Mentrikoski, J.
M. (2011). Multicomponent behavioral treatment for chronic combat-related posttraumatic stress disorder: A randomized controlled
trial. Journal of Anxiety Disorders, 25(2), 224–231. https://doi.
org/10.1016/j.janxdis.2010.09.006
Belleville, G., Dubé-Frenette, M., & Rousseau, A. (2018). Efficacy of
imagery rehearsal therapy and cognitive behavioral therapy in sexual assault victims with posttraumatic stress disorder: A randomized
controlled trial. Journal of Traumatic Stress, 31(4), 591–601. https://
doi.org/10.1002/jts.22306
Berger, W., Mendlowicz, M. V., Marques-Portella, C., Kinrys, G.,
Fontenelle, L. F., Marmar, C. R., & Figueira, I. (2009). Pharmacologic
|
29 of 36
alternatives to antidepressants in posttraumatic stress disorder:
A systematic review. Progress in Neuro-Psychopharmacology &
Biological Psychiatry, 33(2), 169–180. https://doi.org/10.1016/j.
pnpbp.2008.12.004
Bichescu, D., Neuner, F., Schauer, M., & Elbert, T. (2007). Narrative
exposure therapy for political imprisonment-related chronic posttraumatic stress disorder and depression. Behaviour Research
and Therapy, 45(9), 2212–2220. https://doi.org/10.1016/j.
brat.2006.12.006
Blanchard, E. B., Hickling, E. J., Devineni, T., Veazey, C. H.,
Galovski, T. E., Mundy, E., … Buckley, T. C. (2003). A controlled evaluation of cognitive behaviorial therapy for posttraumatic stress in motor vehicle accident survivors. Behaviour
Research and Therapy, 41(1), 79–96. https://doi.org/10.1016/
S0005-7967(01)00131-0
Brady, K., Pearlstein, T., Asnis, G. M., Baker, D., Rothbaum, B., Sikes,
C. R., & Farfel, G. M. (2000). Efficacy and safety of sertraline
treatment of posttraumatic stress disorder: A randomized controlled trial. JAMA, 283(14), 1837–1844. https://doi.org/10.1001/
jama.283.14.1837
Breslau, N., Peterson, E. L., Poisson, L. M., Schultz, L. R., & Lucia, V.
C. (2004). Estimating post-traumatic stress disorder in the community: Lifetime perspective and the impact of typical traumatic events.
Psychological Medicine, 34, 889–898. https://doi.org/10.1017/
S0033291703001612
Bryant, R. A., Ekasawin, S., Chakrabhand, S., Suwanmitri, S.,
Duangchun, O., & Chantaluckwong, T. (2011). A randomized controlled effectiveness trial of cognitive behavior therapy for post-traumatic stress disorder in terrorist-affected people in Thailand. World
Psychiatry, 10(3), 205–209.
Bryant, R. A., Kenny, L., Rawson, N., Cahill, C., Joscelyne, A., Garber,
B., … Nickerson, A. (2018). Efficacy of exposure-based cognitive behaviour therapy for post-traumatic stress disorder in emergency service personnel: A randomised clinical trial. Psychological
Medicine, 49(09), 1565–1573. https://doi.org/10.1017/S003329171
8002234
Bryant, R., Mastrodomenico, J., Hopwood, S., Kenny, L., Cahill, C.,
Kandris, E., & Taylor, K. (2013). Augmenting cognitive behaviour
therapy for post-traumatic stress disorder with emotion tolerance
training: A randomized controlled trial. Psychological Medicine,
43(10), 2153–2160. https://doi.org/10.1017/S0033291713000068
Bryant, R. A., Moulds, M. L., Guthrie, R. M., Dang, S. T., & Nixon,
R. D. (2003). Imaginal exposure alone and imaginal exposure with
cognitive restructuring in treatment of posttraumatic stress disorder.
Journal of Consulting and Clinical Psychology, 71(4), 706–712.
https://doi.org/10.1037/0022-006X.71.4.706
Buhmann, C. B., Nordentoft, M., Ekstroem, M., Carlsson, J., &
Mortensen, E. L. (2016). The effect of flexible cognitive-behavioural therapy and medical treatment, including antidepressants
on post-traumatic stress disorder and depression in traumatised refugees: Pragmatic randomised controlled clinical trial. The British
Journal of Psychiatry, 208(3), 252–259. https://doi.org/10.1192/
bjp.bp.114.150961
Butollo, W., Karl, R., König, J., & Rosner, R. (2016). A randomized controlled clinical trial of dialogical exposure therapy versus cognitive
processing therapy for adult outpatients suffering from PTSD after
type I trauma in adulthood. Psychotherapy and Psychosomatics,
85(1), 16–26. https://doi.org/10.1159/000440726
Carletto, S., Borghi, M., Bertino, G., Oliva, F., Cavallo, M., Hofmann,
A., … Ostacoli, L. (2016). Treating post-traumatic stress disorder in
30 of 36
|
patients with multiple sclerosis: A randomized controlled trial comparing the efficacy of eye movement desensitization and reprocessing and relaxation therapy. Frontiers in Psychology, 7, 526. https://
doi.org/10.3389/fpsyg.2016.00526
Carlson, J. G., Chemtob, C. M., Rusnak, K., Hedlund, N. L., &
Muraoka, M. Y. (1998). Eye movement desensitization and reprocessing (EDMR) treatment for combat-related posttraumatic stress
disorder. Journal of Traumatic Stress, 11(1), 3–24. https://doi.
org/10.1023/A:1024448814268
Čavaljuga, S., Liačnin, I., Mulabegović, N., & Potkonjak, D. (2003).
Therapeutic effects of two antidepressant agents in the treatment
of posttraumatic stress disorder (PTSD). Bosnian Journal of Basic
Medical Sciences, 3(2), 12–16.
Celik, C., Ozdemir, B., Ozmenler, K. N., Yelboga, Z., Balikci, A., Oznur,
T., … Bozkurt, A. (2011). Efficacy of paroxetine and amitriptyline
in posttraumatic stress disorder: An open-label comparative study.
Bulletin of Clinical Psychopharmacology, 21(3), 179–185. https://
doi.org/10.5455/bcp.20110627111141
Chard, K. M. (2005). An evaluation of cognitive processing therapy for
the treatment of posttraumatic stress disorder related to childhood
sexual abuse. Journal of Consulting and Clinical Psychology, 73(5),
965–971. https://doi.org/10.1037/0022-006X.73.5.965
Chung, M. Y., Min, K. H., Jun, Y. J., Kim, S. S., Kim, W. C., & Jun, E.
M. (2004). Efficacy and tolerability of mirtazapine and sertraline
in Korean veterans with posttraumatic stress disorder: A randomized open label trial. Human Psychopharmacology: Clinical and
Experimental, 19(7), 489–494. https://doi.org/10.1002/hup.615
Cigrang, J. A., Rauch, S. A., Mintz, J., Brundige, A. R., Mitchell, J. A.,
Najera, E., … Peterson, A. L. (2017). Moving effective treatment for
posttraumatic stress disorder to primary care: A randomized controlled trial with active duty military. Families, Systems, & Health,
35(4), 450–462. https://doi.org/10.1037/fsh0000315
Cloitre, M., Koenen, K. C., Cohen, L. R., & Han, H. (2002). Skills
training in affective and interpersonal regulation followed by exposure: A phase-based treatment for PTSD related to childhood abuse.
Journal of Consulting and Clinical Psychology, 70(5), 1067–1074.
https://doi.org/10.1037//0022-006X.70.5.1067
Cloitre, M., Stovall-McClough, K. C., Nooner, K., Zorbas, P., Cherry,
S., Jackson, C. L., … Petkova, E. (2010). Treatment for PTSD related to childhood abuse: A randomized controlled trial. American
Journal of Psychiatry, 167(8), 915–924. https://doi.org/10.1176/
appi.ajp.2010.09081247
Coffey, S. F., Schumacher, J. A., Nosen, E., Littlefield, A. K., Henslee,
A. M., Lappen, A., & Stasiewicz, P. R. (2016). Trauma-focused
exposure therapy for chronic posttraumatic stress disorder in alcohol and drug dependent patients: A randomized controlled trial.
Psychology of Addictive Behaviors, 30(7), 778–790. https://doi.
org/10.1037/adb0000201
Connor, K. M., Sutherland, S. M., Tupler, L. A., Malik, M. L., Jonathan,
R., & Davidson, T. (1999). Fluoxetine in post-traumatic stress disorder: Randomised, double-blind study. The British Journal of
Psychiatry, 175(1), 17–22. https://doi.org/10.1192/bjp.175.1.17
Cottraux, J., Note, I., Yao, S. N., de Mey-Guillard, C., Bonasse, F.,
Djamoussian, D., … Chen, Y. (2008). Randomized controlled comparison of cognitive behavior therapy with Rogerian supportive therapy in chronic post-traumatic stress disorder: A 2-year follow-up.
Psychotherapy and Psychosomatics, 77(2), 101–110. https://doi.
org/10.1159/000112887
Crocker, L. D., Jurick, S. M., Thomas, K. R., Keller, A. V., SandersonCimino, M., Boyd, B., … Jak, A. J. (2018). Worse baseline executive
VARKER ET AL.
functioning is associated with dropout and poorer response to trauma-focused treatment for veterans with PTSD and comorbid traumatic brain injury. Behaviour Research and Therapy, 108, 68–77.
https://doi.org/10.1016/j.brat.2018.07.004
Crosby, R. D., Kolotkin, R. L., & Williams, G. R. (2003). Defining clinically meaningful change in health-related quality of life. Journal
of Clinical Epidemiology, 56(5), 395–407. https://doi.org/10.1016/
s0895-4356(03)00044-1
Cuijpers, P. (2019). Targets and outcomes of psychotherapies for mental
disorders: An overview. World Psychiatry, 18(3), 276–285. https://
doi.org/10.1002/wps.20661
Davidson, J., Baldwin, D., Stein, D. J., Kuper, E., Benattia, I., Ahmed,
S., … Musgnung, J. (2006). Treatment of posttraumatic stress disorder with venlafaxine extended release: A 6-month randomized
controlled trial. Archives of General Psychiatry, 63(10), 1158–1165.
https://doi.org/10.1001/archpsyc.63.10.1158
Davidson, J. R. T., Connor, K. M., Hertzberg, M. A., Weisler, R. H.,
Wilson, W. H., & Payne, V. M. (2005). Maintenance therapy with
fluoxetine in posttraumatic stress disorder: A placebo-controlled discontinuation study. Journal of Clinical Psychopharmacology, 25(2),
166–169. https://doi.org/10.1097/01.jcp.0000155817.21467.6c
Davidson, J., Rothbaum, B. O., Tucker, P., Asnis, G., Benattia, I., &
Musgnung, J. J. (2006). Venlafaxine extended release in posttraumatic stress disorder: A sertraline-and placebo-controlled study.
Journal of Clinical Psychopharmacology, 26(3), 259–267. https://
doi.org/10.1097/01.jcp.0000222514.71390.c1
Davidson, J. R. T., Rothbaum, B. O., van der Kolk, B. A., Sikes, C. R.,
& Farfel, G. M. (2001). Multicenter, double-blind comparison of
sertraline and placebo in the treatment of posttraumatic stress disorder. Archives of General Psychiatry, 58(5), 485–492. https://doi.
org/10.1001/archpsyc.58.5.485
de Bont, P. A., van Minnen, A., & de Jongh, A. (2013). Treating PTSD
in patients with psychosis: A within-group controlled feasibility
study examining the efficacy and safety of evidence-based PE and
EMDR protocols. Behavior Therapy, 44(4), 717–730. https://doi.
org/10.1016/j.beth.2013.07.002
de Kleine, R. A., Hendriks, G.-J., Kusters, W. J., Broekman, T. G.,
& van Minnen, A. (2012). A randomized placebo-controlled trial
of D-cycloserine to enhance exposure therapy for posttraumatic
stress disorder. Biological Psychiatry, 71(11), 962–968. https://doi.
org/10.1016/j.biopsych.2012.02.033
Difede, J., Malta, L. S., Best, S., Henn-Haase, C., Metzler, T., Bryant,
R., & Marmar, C. (2007). A randomized controlled clinical treatment trial for World Trade Center attack-related PTSD in disaster
workers. The Journal of Nervous and Mental Disease, 195(10),
861–865. https://doi.org/10.1097/NMD.0b013e3181568612
Dunlop, B. W., Kaye, J. L., Youngner, C., & Rothbaum, B. (2014).
Assessing treatment-resistant posttraumatic stress disorder: The
Emory Treatment Resistance Interview for PTSD (E-TRIP).
Behavioural Sciences, 4, 511–527. https://doi.org/10.3390/bs404
0511
Dunne, R. L., Kenardy, J., & Sterling, M. (2012). A randomized controlled trial of cognitive-behavioral therapy for the treatment of
PTSD in the context of chronic whiplash. The Clinical Journal of
Pain, 28(9), 755–765. https://doi.org/10.1097/AJP.0b013e3182
43e16b
Ehlers, A., Clark, D. M., Hackmann, A., McManus, F., & Fennell,
M. (2005). Cognitive therapy for post-traumatic stress disorder:
Development and evaluation. Behaviour Research and Therapy,
43(4), 413–431. https://doi.org/10.1016/j.brat.2004.03.006
VARKER ET AL.
Ehlers, A., Clark, D. M., Hackmann, A., McManus, F., Fennell, M.,
Herbert, C., & Mayou, R. (2003). A randomized controlled trial
of cognitive therapy, a self-help booklet, and repeated assessments
as early interventions for posttraumatic stress disorder. Archives of
General Psychiatry, 60(10), 1024–1032. https://doi.org/10.1001/
archpsyc.60.10.1024
Ehlers, A., Hackmann, A., Grey, N., Wild, J., Liness, S., Albert, I., …
Clark, D. M. (2014). A randomized controlled trial of 7-day intensive and standard weekly cognitive therapy for PTSD and emotion-focused supportive therapy. American Journal of Psychiatry,
171(3), 294–304. https://doi.org/10.1176/appi.ajp.2013.13040552
Ertl, V., Pfeiffer, A., Schauer, E., Elbert, T., & Neuner, F. (2011).
Community-implemented trauma therapy for former child soldiers
in Northern Uganda: A randomized controlled trial. JAMA, 306(5),
503–512. https://doi.org/10.1001/jama.2011.1060
Fecteau, G., & Nicki, R. (1999). Cognitive behavioural treatment of post
traumatic stress disorder after motor vehicle accident. Behavioural
and Cognitive Psychotherapy, 27(3), 201–214.
Feeny, N. C., Zoellner, L. A., & Foa, E. B. (2002). Treatment outcome
for chronic PTSD among female assault victims with borderline
personality characteristics: A preliminary examination. Journal of
Personality Disorders, 16(1), 30–40.
Feng, B., Zhang, Y., Luo, L.-Y., Wu, J.-Y., Yang, S.-J., Zhang, N., …
Zhang, Z.-J. (2018). Transcutaneous electrical acupoint stimulation
for post-traumatic stress disorder: Assessor-blinded, randomized
controlled study. Psychiatry and Clinical Neurosciences, 73(4),
179–186. https://doi.org/10.1111/pcn.12810
Feske, U. (2008). Treating low-income and minority women with posttraumatic stress disorder: A pilot study comparing prolonged exposure and treatment as usual conducted by community therapists.
Journal of Interpersonal Violence, 23(8), 1027–1040. https://doi.
org/10.1177/0886260507313967
Foa, E. B. (1995). Manual for the Posttraumatic Diagnostic Scale
(PDS). Minneapolis: National Computer Systems Assessments.
Foa, E. B., Dancu, C. V., Hembree, E. A., Jaycox, L. H., Meadows,
E. A., & Street, G. P. (1999). A comparison of exposure therapy,
stress inoculation training, and their combination for reducing
posttraumatic stress disorder in female assault victims. Journal of
Consulting and Clinical Psychology, 67(2), 194–200. https://doi.
org/10.1037//0022-006x.67.2.194
Foa, E. B., McLean, C. P., Zang, Y., Rosenfield, D., Yadin, E., Yarvis,
J. S., … Peterson, A. L. (2018). Effect of prolonged exposure therapy delivered over 2 weeks vs 8 weeks vs present-centered therapy
on PTSD symptom severity in military personnel: A randomized
clinical trial. JAMA, 319(4), 354–364. https://doi.org/10.1001/
jama.2017.21242
Foa, E. B., Rothbaum, B. O., Riggs, D. S., & Murdock, T. B. (1991).
Treatment of posttraumatic stress disorder in rape victims: A comparison between cognitive-behavioral procedures and counseling.
Journal of Consulting and Clinical Psychology, 59(5), 715–723.
https://doi.org/10.1037/0022-006X.59.5.715
Foa, E. B., Zoellner, L. A., Feeny, N. C., Hembree, E. A., & AlvarezConrad, J. (2002). Does imaginal exposure exacerbate PTSD symptoms? Journal of Consulting and Clinical Psychology, 70(4), 1022.
https://doi.org/10.1037//0022-006X.70.4.1022
Foa, E. B., Yusko, D. A., McLean, C. P., Suvak, M. K., Bux, D. A.,
Oslin, D., … Volpicelli, J. (2013). Concurrent naltrexone and prolonged exposure therapy for patients with comorbid alcohol dependence and PTSD: A randomized clinical trial. JAMA, 310(5), 488–
495. https://doi.org/10.1001/jama.2013.8268
|
31 of 36
Fonzo, G. A., Goodkind, M. S., Oathes, D. J., Zaiko, Y. V., Harvey,
M., Peng, K. K., … Etkin, A. (2017). PTSD psychotherapy outcome
predicted by brain activation during emotional reactivity and regulation. American Journal of Psychiatry, 174(12), 1163–1174. https://
doi.org/10.1176/appi.ajp.2017.16091072
Forbes, D., Creamer, M., Bisson, J. I., Cohen, J. A., Crow, B. E., Foa, E.
B., … Ursano, R. J. (2010). A guide to guidelines for the treatment
of PTSD and related conditions. Journal of Traumatic Stress, 23,
537–552. https://doi.org/10.1002/jts.20565
Forbes, D., Lloyd, D., Nixon, R., Elliott, P., Varker, T., Perry, D., …
Creamer, M. (2012). A multisite randomized controlled effectiveness trial of cognitive processing therapy for military-related posttraumatic stress disorder. Journal of Anxiety Disorders, 26(3), 442–
452. https://doi.org/10.1016/j.janxdis.2012.01.006
Forbes, D., Pedlar, D., Adler, A. B., Bennett, C., Bryant, R., Busuttil,
W., … Wessely, S. (2019). Treatment of military-related posttraumatic stress disorder: Challenges, innovations, and the way
forward. International Review of Psychiatry, 31(1), https://doi.
org/10.1080/09540261.2019.1595545
Ford, J. D., Grasso, D. J., Greene, C. A., Slivinsky, M., & DeViva, J. C.
(2018). Randomized clinical trial pilot study of prolonged exposure
versus present centred affect regulation therapy for PTSD and anger
problems with male military combat veterans. Clinical Psychology
and Psychotherapy, 25(5), 641–649. https://doi.org/10.1002/
cpp.2194
Frank, E., Prien, R. F., Jarrett, R. B., Keller, M. B., Kupfer, D. J., Lavori,
P. W., … Weissman, M. M. (1991). Conceptualization and rationale for consensus definitions of terms in major depressive disorder: Remission, recovery, relapse, and recurrence. Archives of
General Psychiatry, 48(9), 851–855. https://doi.org/10.1001/archp
syc.1991.01810330075011
Friedman, M. J., Marmar, C. R., Baker, D. G., Sikes, C. R., & Farfel,
G. M. (2007). Randomized, double-blind comparison of sertraline
and placebo for posttraumatic stress disorder in a Department of
Veterans Affairs setting. The Journal of Clinical Psychiatry, 68,
711–720.
Galovski, T. E., Blain, L. M., Mott, J. M., Elwood, L., & Houle, T.
(2012). Manualized therapy for PTSD: Flexing the structure of
cognitive processing therapy. Journal of Consulting and Clinical
Psychology, 80(6), 968–981. https://doi.org/10.1037/a0030600
Gerger, H., Munder, T., & Barth, J. (2014). Specific and nonspecific
psychological interventions for PTSD symptoms: A meta-analysis with problem complexity as a moderator. Journal of Clinical
Psychology, 70, 601–615. https://doi.org/10.1002/jclp.22059
Gersons, B. P., Carlier, I. V., Lamberts, R. D., & van der Kolk, B. A. (2000).
Randomized clinical trial of brief eclectic psychotherapy for police officers with posttraumatic stress disorder. Journal of Traumatic Stress,
13(2), 333–347. https://doi.org/10.1023/A:1007793803627
Goldberg, J., Magruder, K. M., Forsberg, C. W., Friedman, M. J., Litz,
B. T., Vaccarino, V., … Smith, N. L. (2016). Prevalence of posttraumatic stress disorder in aging Vietnam-era veterans: Veterans
Administration Cooperative Study 569: Course and consequences
of posttraumatic stress disorder in Vietnam-era veteran twins.
American Journal of Geriatric Psychiatry, 24, 181–191. https://doi.
org/10.1016/j.jagp.2015.05.004
Haller, M., Norman, S. B., Cummins, K., Trim, R. S., Xu, X., Cui, R.,
… Tate, S. R. (2016). Integrated cognitive behavioral therapy versus
cognitive processing therapy for adults with depression, substance
use disorder, and trauma. Journal of Substance Abuse Treatment, 62,
38–48. https://doi.org/10.1016/j.jsat.2015.11.005
32 of 36
|
Harned, M. S., Korslund, K. E., & Linehan, M. M. (2014). A pilot randomized controlled trial of dialectical behavior therapy with and
without the dialectical behavior therapy prolonged exposure protocol for suicidal and self-injuring women with borderline personality
disorder and PTSD. Behaviour Research and Therapy, 55, 7–17.
https://doi.org/10.1016/j.brat.2014.01.008
Hensel-Dittmann, D., Schauer, M., Ruf, M., Catani, C., Odenwald, M.,
Elbert, T., & Neuner, F. (2011). Treatment of traumatized victims
of war and torture: A randomized controlled comparison of narrative exposure therapy and stress inoculation training. Psychotherapy
and Psychosomatics, 80(6), 345–352. https://doi.org/10.1159/00032
7253
Hertzberg, M. A., Feldman, M. E., Beckham, J. C., Kudler, H. S., &
Davidson, J. R. (2000). Lack of efficacy for fluoxetine in PTSD:
A placebo controlled trial in combat veterans. Annals of Clinical
Psychiatry, 12(2), 101–105. https://doi.org/10.1023/a:10090
76231175
Hien, D. A., Levin, F. R., Ruglass, L. M., López-Castro, T., Papini, S.,
Hu, M.-C., … Herron, A. (2015). Combining seeking safety with
sertraline for PTSD and alcohol use disorders: A randomized controlled trial. Journal of Consulting and Clinical Psychology, 83(2),
359–369. https://doi.org/10.1037/a0038719
Hinton, D. E., Chhean, D., Pich, V., Safren, S. A., Hofmann, S. G.,
& Pollack, M. H. (2005). A randomized controlled trial of cognitive-behavior therapy for Cambodian refugees with treatment-resistant PTSD and panic attacks: A cross-over design. Journal of
Traumatic Stress, 18(6), 617–629. https://doi.org/10.1002/jts.20070
Högberg, G., Pagani, M., Sundin, Ö., Soares, J., Åberg-Wistedt, A.,
Tärnell, B., & Hällström, T. (2007). On treatment with eye movement desensitization and reprocessing of chronic post-traumatic
stress disorder in public transportation workers: A randomized controlled trial. Nordic Journal of Psychiatry, 61(1), 54–61. https://doi.
org/10.1080/08039480601129408
Ironson, G., Freund, B., Strauss, J., & Williams, J. (2002). Comparison
of two treatments for traumatic stress: A community-based study
of EMDR and prolonged exposure. Journal of Clinical Psychology,
58(1), 113–128. https://doi.org/10.1002/jclp.1132
Jacob, N., Neuner, F., Maedl, A., Schaal, S., & Elbert, T. (2014).
Dissemination of psychotherapy for trauma spectrum disorders in
postconflict settings: A randomized controlled trial in Rwanda.
Psychotherapy and Psychosomatics, 83(6), 354–363. https://doi.
org/10.1159/000365114
Jacobson, N. S., & Truax, P. (1991). Clinical significance: A statistical
approach to defining meaningful change in psychotherapy research.
Journal of Consulting and Clinical Psychology, 59(1), 12–19.
https://doi.org/10.1037/0022-006X.59.1.12
Keller, M. B. (2003). Past, present, and future directions for defining optimal treatment outcome in depression: Remission and
beyond. JAMA, 289(23), 3152–3160. https://doi.org/10.1001/
jama.289.23.3152
Karatzias, T., Power, K., Brown, K., McGoldrick, T., Begum, M.,
Young, J., … Adams, S. (2011). A controlled comparison of the
effectiveness and efficiency of two psychological therapies for posttraumatic stress disorder: Eye movement desensitization and reprocessing vs. emotional freedom techniques. The Journal of Nervous
and Mental Disease, 199(6), 372–378. https://doi.org/10.1097/
NMD.0b013e31821cd262
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., &
Walters, E. W. (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey
VARKER ET AL.
replication. Archives of General Psychiatry, 62, 593–602. https://
doi.org/10.1001/archpsyc.62.6.593
Koek, R. J., Schwartz, H. N., Scully, S., Langevin, J.-P., Spangler,
S., Korotinsky, A., … Leuchter, A. (2016). Treatment-refractory
posttraumatic stress disorder (TRPTSD): A review and framework for the future. Progress in Neuro-Psychopharmacology &
Biological Psychiatry, 70, 170–218. https://doi.org/10.1016/j.
pnpbp.2016.01.015
Kottner, J., & Streiner, D. L. (2011). The difference between reliability
and agreement. Journal of Clinical Epidemiology, 64(6), 701–702.
https://doi.org/10.1016/j.jclinepi.2010.12.001
Kozel, F. A., Motes, M. A., Didehbani, N., DeLaRosa, B., Bass, C.,
Schraufnagel, C. D., … Hart, J. (2018). Repetitive TMS to augment
cognitive processing therapy in combat veterans of recent conflicts with PTSD: A randomized clinical trial. Journal of Affective
Disorders, 229, 506–514. 1016/j.jad.2017.12.046
Lam, R. W., Parikh, S. V., Michalak, E. E., Dewa, C. S., & Kennedy,
S. H. (2015). Canadian Network for Mood and Anxiety Treatments
(CANMAT) consensus recommendations for functional outcomes
in major depressive disorder. Annals of Clinical Psychiatry, 27(2),
142–149.
Langkaas, T. F., Hoffart, A., Øktedalen, T., Ulvenes, P. G., Hembree, E.
A., & Smucker, M. (2017). Exposure and non-fear emotions: A randomized controlled study of exposure-based and rescripting-based
imagery in PTSD treatment. Behaviour Research and Therapy, 97,
33–42. https://doi.org/10.1016/j.brat.2017.06.007
Larsen, S. E., Fleming, C., & Resick, P. A. (2019). Residual symptoms
following empirically supported treatment for PTSD. Psychological
Trauma: Theory, Research, Practice, and Policy, 11(2), 207–215.
https://doi.org/10.1037/tra0000384
Lee, C., Gavriel, H., Drummond, P., Richards, J., & Greenwald, R.
(2002). Treatment of PTSD: Stress inoculation training with
prolonged exposure compared to EMDR. Journal of Clinical
Psychology, 58(9), 1071–1089. https://doi.org/10.1002/jclp.10039
Li, W., Ma, Y.-B., Yang, Q., Li, B.-L., Meng, Q.-G., & Zhang, Y.
(2017). Effect and safety of sertraline for treat posttraumatic stress
disorder: A multicenter randomised controlled study. International
Journal of Psychiatry in Clinical Practice, 21(2), 151–155. https://
doi.org/10.1080/13651501.2017.1291838
Lindauer, R j l, Booij, J., Habraken, J b a, van Meijel, E p m, Uylings,
H b m, Olff, M., … Gersons, B p r (2008). Effects of psychotherapy
on regional cerebral blood flow during trauma imagery in patients
with post-traumatic stress disorder: A randomized clinical trial.
Psychological Medicine, 38(4), 543–554. https://doi.org/10.1017/
S0033291707001432
Lindauer, R. J., Gersons, B. P., van Meijel, E. P., Blom, K., Carlier, I.
V., Vrijlandt, I., & Olff, M. (2005). Effects of brief eclectic psychotherapy in patients with posttraumatic stress disorder: Randomized
clinical trial. Journal of Traumatic Stress, 18(3), 205–212. https://
doi.org/10.1002/jts.20029
Lindauer, R. J. L., Vlieger, E.-J., Jalink, M., Olff, M., Carlier, I. V. E.,
Majoie, C. B. L. M., … Gersons, B. P. R. (2005). Effects of psychotherapy on hippocampal volume in out-patients with post-traumatic stress disorder: A MRI investigation. Psychological Medicine,
35(10), 1421–1431. https://doi.org/10.1017/S0033291705005246
Litz, B. T., Salters-Pedneault, K., Steenkamp, M. M., Hermos, J. A.,
Bryant, R. A., Otto, M. W., & Hofmann, S. G. (2012). A randomized placebo-controlled trial of D-cycloserine and exposure therapy
for posttraumatic stress disorder. Journal of Psychiatric Research,
46(9), 1184–1190. https://doi.org/10.1016/j.jpsychires.2012.05.006
VARKER ET AL.
Maercker, A., Zöllner, T., Menning, H., Rabe, S., & Karl, A. (2006).
Dresden PTSD treatment study: Randomized controlled trial of
motor vehicle accident survivors. BMC Psychiatry, 6(1), 29. https://
doi.org/10.1186/1471-244X-6-29
Maieritsch, K. P., Smith, T. L., Hessinger, J. D., Ahearn, E. P., Eickhoff,
J. C., & Zhao, Q. (2016). Randomized controlled equivalence trial
comparing videoconference and in person delivery of cognitive processing therapy for PTSD. Journal of Telemedicine and Telecare,
22(4), 238–243. https://doi.org/10.1177/1357633X1559609
Marcus, S. V., Marquis, P., & Sakai, C. (1997). Controlled study of treatment of PTSD using EMDR in an HMO setting. Psychotherapy:
Theory, Research, Practice, Training, 34(3), 307.
Markowitz, J. C., Petkova, E., Neria, Y., Van Meter, P. E., Zhao, Y.,
Hembree, E., … Marshall, R. D. (2015). Is exposure necessary? A
randomized clinical trial of interpersonal psychotherapy for PTSD.
American Journal of Psychiatry, 172(5), 430–440. https://doi.
org/10.1176/appi.ajp.2014.14070908
Marks, I., Lovell, K., Noshirvani, H., Livanou, M., & Thrasher, S.
(1998). Treatment of posttraumatic stress disorder by exposure
and/or cognitive restructuring: A controlled study. Archives of
General Psychiatry, 55(4), 317–325. https://doi.org/10.1001/archp
syc.55.4.317
Marshall, R. D., Beebe, K. L., Oldham, M., & Zaninelli, R. (2001).
Efficacy and safety of paroxetine treatment for chronic PTSD:
A fixed-dose, placebo-controlled study. American Journal of
Psychiatry, 158(12), 1982–1988. https://doi.org/10.1176/appi.
ajp.158.12.1982
Marshall, R. D., Lewis-Fernandez, R., Blanco, C., Simpson, H. B., Lin,
S.-H., Vermes, D., … Liebowitz, M. R. (2007). A controlled trial
of paroxetine for chronic PTSD, dissociation, and interpersonal
problems in mostly minority adults. Depression and Anxiety, 24(2),
77–84. https://doi.org/10.1002/da.20176
Martenyi, F., Brown, E. B., & Caldwell, C. D. (2007). Failed efficacy of
fluoxetine in the treatment of posttraumatic stress disorder: Results
of a fixed-dose, placebo-controlled study. Journal of Clinical
Psychopharmacology, 27(2), 166–170. https://doi.org/10.1097/
JCP.0b013e31803308ce
Martenyi, F., Brown, E. B., Zhang, H., Prakash, A., & Koke, S. C.
(2002). Fluoxetine versus placebo in posttraumatic stress disorder.
The Journal of Clinical Psychiatry, 63(3), 199–206. https://doi.
org/10.4088/jcp.v63n0305
McDonagh, A., Friedman, M., McHugo, G., Ford, J., Sengupta, A.,
Mueser, K., … Descamps, M. (2005). Randomized trial of cognitive-behavioral therapy for chronic posttraumatic stress disorder
in adult female survivors of childhood sexual abuse. Journal of
Consulting and Clinical Psychology, 73(3), 515–524. https://doi.
org/10.1037/0022-006X.73.3.515
McEvoy, P. M., Grove, R., & Slade, T. (2011). Epidemiology of anxiety disorders in the Australian general population: Findings of the
2007 Australian National Survey of Mental Health and Wellbeing.
Australian and New Zealand Journal of Psychiatry, 45, 957–967.
https://doi.org/10.3109/00048674.2011.624083
McFarlane, A. C. (2019). Treatment resistance in posttraumatic
stress disorder. In Y. K. Kim (Ed.), Treatment resistance in
psychiatry (pp. 151–164). Singapore: Springer. https://doi.
org/10.1007/978-981-10-4358-1_10
McGovern, M. P., Lambert-Harris, C., Alterman, A. I., Xie, H., &
Meier, A. (2011). A randomized controlled trial comparing integrated cognitive behavioral therapy versus individual addiction
counseling for co-occurring substance use and posttraumatic stress
|
33 of 36
disorders. Journal of Dual Diagnosis, 7(4), 207–227. https://doi.
org/10.1080/15504263.2011.620425
McGovern, M. P., Lambert-Harris, C., Xie, H., Meier, A., McLeman, B.,
& Saunders, E. (2015). A randomized controlled trial of treatments
for co-occurring substance use disorders and post-traumatic stress
disorder. Addiction, 110(7), 1194–1204. https://doi.org/10.1111/
add.12943
McLay, R. N., Baird, A., Webb-Murphy, J., Deal, W., Tran, L., Anson,
H., … Johnston, S. (2017). A randomized, head-to-head study of
virtual reality exposure therapy for posttraumatic stress disorder.
Cyberpsychology, Behavior, and Social Networking, 20(4), 218–
224. https://doi.org/10.1089/cyber.2016.0554
Metcalf, O., Stone, C., Hinton, M., O’Donnell, M., Hopwood, M.,
McFarlane, A., … Varker, T. (2019). Treatment augmentation
for posttraumatic stress disorder: A systematic review. Clinical
Psychology: Science and Practice, 27(1), e12310.
Mills, K. L., Teesson, M., Back, S. E., Brady, K. T., Baker, A. L.,
Hopwood, S., … Ewer, P. L. (2012). Integrated exposure-based therapy for co-occurring posttraumatic stress disorder and substance dependence: A randomized controlled trial. JAMA, 308(7), 690–699.
https://doi.org/10.1001/jama.2012.9071
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G.; The PRISMA
Group (2009). Preferred reporting items for systematic reviews and
meta-analyses: The PRISMA statement. BMJ, 339, b2535. https://
doi.org/10.1136/bmj.b2535
Monson, C. M., Schnurr, P. P., Resick, P. A., Friedman, M. J., Young-Xu,
Y., & Stevens, S. P. (2006). Cognitive processing therapy for veterans with military-related posttraumatic stress disorder. Journal of
Consulting and Clinical Psychology, 74(5), 898–907. https://doi.
org/10.1037/0022-006X.74.5.898
Morland, L. A., Mackintosh, M.-A., Rosen, C. S., Willis, E., Resick, P.,
Chard, K., & Frueh, B. C. (2015). Telemedicine versus in-person delivery of cognitive processing therapy for women with posttraumatic
stress disorder: A randomized noninferiority trial. Depression and
Anxiety, 32(11), 811–820. https://doi.org/10.1002/da.22397
Mueser, K. T., Gottlieb, J. D., Xie, H., Lu, W., Yanos, P. T., Rosenberg,
S. D., … Wolfe, R. S. (2015). Evaluation of cognitive restructuring
for post-traumatic stress disorder in people with severe mental illness. The British Journal of Psychiatry, 206(6), 501–508. https://
doi.org/10.1192/bjp.bp.114.147926
Mueser, K. T., Rosenberg, S. D., Xie, H., Jankowski, M. K., Bolton, E.
E., Lu, W., … Wolfe, R. (2008). A randomized controlled trial of cognitive-behavioral treatment for posttraumatic stress disorder in severe mental illness. Journal of Consulting and Clinical Psychology,
76(2), 259. https://doi.org/10.1037/0022-006X.76.2.259
Nacasch, N., Huppert, J. D., Su, Y.-J., Kivity, Y., Dinshtein, Y., Yeh, R.,
& Foa, E. B. (2015). Are 60-minute prolonged exposure sessions
with 20-minute imaginal exposure to traumatic memories sufficient
to successfully treat PTSD? A randomized noninferiority clinical
trial. Behavior Therapy, 46(3), 328–341. https://doi.org/10.1016/j.
beth.2014.12.002
Nemeroff, C. B., Bremner, J. D., Foa, E. B., Mayberg, H. S., North, C.
S., & Stein, M. B. (2006). Posttraumatic stress disorder: A state-ofthe-science review. Journal of Psychiatric Research, 40(1), 1–21.
https://doi.org/10.1016/j.jpsychires.2005.07.005
Neuner, F., Kurreck, S., Ruf, M., Odenwald, M., Elbert, T., & Schauer,
M. (2010). Can asylum-seekers with posttraumatic stress disorder be
successfully treated? A randomized controlled pilot study. Cognitive
Behaviour Therapy, 39(2), 81–91. https://doi.org/10.1080/16506
070903121042
34 of 36
|
Neuner, F., Onyut, P. L., Ertl, V., Odenwald, M., Schauer, E., & Elbert,
T. (2008). Treatment of posttraumatic stress disorder by trained lay
counselors in an African refugee settlement: A randomized controlled trial. Journal of Consulting and Clinical Psychology, 76(4),
686–694. https://doi.org/10.1037/0022-006X.76.4.686
Neuner, F., Schauer, M., Klaschik, C., Karunakara, U., & Elbert,
T. (2004). A comparison of narrative exposure therapy, supportive counseling, and psychoeducation for treating posttraumatic stress disorder in an African refugee settlement. Journal of
Consulting and Clinical Psychology, 72(4), 579–587. https://doi.
org/10.1037/0022-006X.72.4.579
Nidich, S., Mills, P. J., Rainforth, M., Heppner, P., Schneider, R. H.,
Rosenthal, N. E., … Rutledge, T. (2018). Non-trauma-focused meditation versus exposure therapy in veterans with post-traumatic stress
disorder: A randomised controlled trial. The Lancet Psychiatry,
5(12), 975–986. https://doi.org/10.1016/S2215-0366(18)30384-5
Nijdam, M. J., Gersons, B. P., Reitsma, J. B., de Jongh, A., & Olff,
M. (2012). Brief eclectic psychotherapy v. eye movement desensitisation and reprocessing therapy for post-traumatic stress disorder:
Randomised controlled trial. The British Journal of Psychiatry,
200(3), 224–231. https://doi.org/10.1192/bjp.bp.111.099234
Olatunji, B. O., Cisler, J. M., & Tolin, D. F. (2007). Quality of life in
the anxiety disorders: A meta-analytic review. Clinical Psychology
Review, 27, 572–581. https://doi.org/10.1016/j.cpr.2007.01.015
Önder, E., Tural, Ü., & Aker, T. (2006). A comparative study of fluoxetine, moclobemide, and tianeptine in the treatment of posttraumatic stress disorder following an earthquake. European Psychiatry,
21(3), 174–179. https://doi.org/10.1016/j.eurpsy.2005.03.007
Orang, T., Ayoughi, S., Moran, J. K., Ghaffari, H., Mostafavi, S.,
Rasoulian, M., & Elbert, T. (2018). The efficacy of narrative exposure therapy in a sample of Iranian women exposed to ongoing intimate partner violence: A randomized controlled trial.
Clinical Psychology & Psychotherapy, 25(6), 827–841. https://doi.
org/10.1002/cpp.2318
Pacella, M. L., Armelie, A., Boarts, J., Wagner, G., Jones, T., Feeny,
N., & Delahanty, D. L. (2012). The impact of prolonged exposure
on PTSD symptoms and associated psychopathology in people living with HIV: A randomized test of concept. AIDS and Behavior,
16(5), 1327–1340. https://doi.org/10.1007/s10461-011-0076-y
Pallanti, S., Hollander, E., Bienstock, C., Koran, L., Leckman, J., Marazziti,
D., … International Treatment OCD Consortium (2002). Treatment
non-response in OCD: Methodological issues and operational definitions. International Journal of Neuropsychopharmacology, 5(2),
181–191. https://doi.org/10.1017/S1461145702002900
Panahi, Y., Moghaddam, B. R., Sahebkar, A., Nazari, M. A., Beiraghdar,
F., Karami, G., & Saadat, A. (2011). A randomized, double-blind,
placebo-controlled trial on the efficacy and tolerability of sertraline
in Iranian veterans with post-traumatic stress disorder. Psychological
Medicine, 41(10), 2159–2166. https://doi.org/10.1017/S003329171
1000201
Paunović, N. (2011). Exposure inhibition therapy as a treatment for chronic
posttraumatic stress disorder: A controlled pilot study. Psychology,
2(6), 605–614. https://doi.org/10.4236/psych.2011.26093
Popiel, A., Zawadzki, B., Pragłowska, E., & Teichman, Y. (2015).
Prolonged exposure, paroxetine and the combination in the treatment of PTSD following a motor vehicle accident. A randomized
clinical trial – The “TRAKT” study. Journal of Behavior Therapy
and Experimental Psychiatry, 48, 17–26. https://doi.org/10.1016/j.
jbtep.2015.01.002
VARKER ET AL.
Powers, M. B., Medina, J. L., Burns, S., Kauffman, B. Y., Monfils, M.,
Asmundson, G. J. G., … Smits, J. A. J. (2015). Exercise augmentation of exposure therapy for PTSD: Rationale and pilot efficacy
data. Cognitive Behaviour Therapy, 44(4), 314–327. https://doi.
org/10.1080/16506073.2015.1012740
Rauch, S. A. M., Kim, H. M., Powell, C., Tuerk, P. W., Simon, N. M.,
Acierno, R., … Hoge, C. W. (2018). Efficacy of prolonged exposure therapy, sertraline hydrochloride, and their combination among
combat veterans with posttraumatic stress disorder: A randomized clinical trial. JAMA Psychiatry, 76(2), 117–126. https://doi.
org/10.1001/jamapsychiatry.2018.3412
Rauch, S. A. M., King, A. P., Abelson, J., Tuerk, P. W., Smith, E.,
Rothbaum, B. O., … Liberzon, I. (2015). Biological and symptom
changes in posttraumatic stress disorder treatment: A randomized
clinical trial. Depression and Anxiety, 32(3), 204–212. https://doi.
org/10.1002/da.22331
Reger, G. M., Koenen-Woods, P., Zetocha, K., Smolenski, D. J.,
Holloway, K. M., Rothbaum, B. O., … Gahm, G. A. (2016).
Randomized controlled trial of prolonged exposure using imaginal
exposure vs. virtual reality exposure in active duty soldiers with deployment-related posttraumatic stress disorder (PTSD). Journal of
Consulting and Clinical Psychology, 84(11), 946–959. https://doi.
org/10.1037/ccp0000134
Resick, P. A., Galovski, T. E., Uhlmansiek, M. O. B., Scher, C. D.,
Clum, G. A., & Young-Xu, Y. (2008). A randomized clinical trial
to dismantle components of cognitive processing therapy for posttraumatic stress disorder in female victims of interpersonal violence.
Journal of Consulting and Clinical Psychology, 76(2), 243–258.
https://doi.org/10.1037/0022-006X.76.2.243
Resick, P. A., Nishith, P., Weaver, T. L., Astin, M. C., & Feuer, C. A.
(2002). A comparison of cognitive-processing therapy with prolonged exposure and a waiting condition for the treatment of chronic
posttraumatic stress disorder in female rape victims. Journal of
Consulting and Clinical Psychology, 70(4), 867–879. https://doi.
org/10.1037//0022-006X.70.4.867
Resick, P. A., Wachen, J. S., Dondanville, K. A., Pruiksma, K. E.,
Yarvis, J. S., Peterson, A. L., … Young-McCaughan, S. (2017).
Effect of group vs individual cognitive processing therapy in active-duty military seeking treatment for posttraumatic stress disorder: A randomized clinical trial. JAMA Psychiatry, 74(1), 28–36.
https://doi.org/10.1001/jamapsychiatry.2016.2729
Rodriguez, P., Holowka, D. W., & Marx, B. P. (2012). Assessment of
posttraumatic stress disorder-related functional impairment: A review. Journal of Rehabilitation Research and Development, 5, 649–
666. https://doi.org/10.1682/JRRD.2011.09.0162
Rothbaum, B. O., Cahill, S. P., Foa, E. B., Davidson, J. R. T., Compton,
J., Connor, K. M., … Hahn, C.-G. (2006). Augmentation of sertraline with prolonged exposure in the treatment of posttraumatic
stress disorder. Journal of Traumatic Stress, 19(5), 625–638. https://
doi.org/10.1002/jts.20170
Roy, M. J., Francis, J., Friedlander, J., Banks-Williams, L., Lande, R.
G., Taylor, P., … Rothbaum, B. (2010). Improvement in cerebral
function with treatment of posttraumatic stress disorder. Annals of
the New York Academy of Sciences, 1208(1), 142–149. https://doi.
org/10.1111/j.1749-6632.2010.05689.x
Sack, M., Zehl, S., Otti, A., Lahmann, C., Henningsen, P., Kruse, J., &
Stingl, M. (2016). A comparison of dual attention, eye movements,
and exposure only during eye movement desensitization and reprocessing for posttraumatic stress disorder: Results from a randomized
VARKER ET AL.
clinical trial. Psychotherapy and Psychosomatics, 85(6), 357–365.
https://doi.org/10.1159/000447671
Sannibale, C., Teesson, M., Creamer, M., Sitharthan, T., Bryant, R.
A., Sutherland, K., … Peek-O‘Leary, M. (2013). Randomized controlled trial of cognitive behaviour therapy for comorbid post-traumatic stress disorder and alcohol use disorders. Addiction, 108(8),
1397–1410. https://doi.org/10.1111/add.12167
Schaal, S., Elbert, T., & Neuner, F. (2009). Narrative exposure therapy versus interpersonal psychotherapy. Psychotherapy and
Psychosomatics, 78(5), 298–306. https://doi.org/10.1159/00022
9768
Schacht, R. L., Brooner, R. K., King, V. L., Kidorf, M. S., & Peirce,
J. M. (2017). Incentivizing attendance to prolonged exposure for
PTSD with opioid use disorder patients: A randomized controlled
trial. Journal of Consulting and Clinical Psychology, 85(7), 689–
701. https://doi.org/10.1037/ccp0000208
Schardt, C., Adams, M. B., Owens, T., Keitz, S., & Fontelo, P. (2007).
Utilization of the PICO framework to improve searching PubMed
for clinical questions. BMC Medical Informatics and Decision
Making, 7(16), https://doi.org/10.1186/1472-6947-7-16
Schneier, F. R., Campeas, R., Carcamo, J., Glass, A., Lewis-Fernandez,
R., Neria, Y., … Wall, M. M. (2015). Combined mirtazapine and
SSRI treatment of PTSD: A placebo-controlled trial. Depression
and Anxiety, 32(8), 570–579. https://doi.org/10.1002/da.22384
Schneier, F. R., Neria, Y., Pavlicova, M., Hembree, E., Suh, E. J., Amsel,
L., & Marshall, R. D. (2012). Combined prolonged exposure therapy
and paroxetine for PTSD related to the World Trade Center attack:
A randomized controlled trial. American Journal of Psychiatry,
169(1), 80–88. https://doi.org/10.1176/appi.ajp.2011.11020321
Schnurr, P. P., Friedman, M. J., Engel, C. C., Foa, E. B., Shea, M. T.,
Chow, B. K., … Bernardy, N. (2007). Cognitive behavioral therapy for posttraumatic stress disorder in women: A randomized
controlled trial. JAMA, 297(8), 820–830. https://doi.org/10.1001/
jama.297.8.820
Schnurr, P. P., Hayes, A. F., Lunney, C. A., McFall, M., & Uddo, M.
(2006). Longitudinal analysis of the relationship between symptoms
and quality of life in veterans treated for posttraumatic stress disorder. Journal of Consulting and Clinical Psychology, 74(4), 707–
713. https://doi.org/10.1037/0022-006X.74.4.707
Schnurr, P. P., & Lunney, C. A. (2016). Symptom benchmarks of improved quality of life in PTSD. Depression and Anxiety, 33, 247–
255. https://doi.org/10.1002/da.22477
Schnyder, U., Müller, J., Maercker, A., & Wittmann, L. (2011). Brief
eclectic psychotherapy for PTSD: A randomized controlled trial
[Letter to the editor]. Journal of Clinical Psychiatry, 72(4), 564–
566. https://doi.org/10.4088/JCP.10l06247blu
Seo, H.-J., Jung, Y.-E., Bahk, W.-M., Jun, T.-Y., Seo, J.-H.- C.-J., Jung,
Y.-E., … Chae, J.-H. (2010). A comparison of mirtazapine and paroxetine for the treatment of patients with posttraumatic stress disorder: A randomized open-label trial. Clinical Psychopharmacology
and Neuroscience, 8(2), 84–89.
Sloan, D. M., Marx, B. P., Lee, D. J., & Resick, P. A. (2018). A brief
exposure-based treatment vs cognitive processing therapy for posttraumatic stress disorder: A randomized noninferiority clinical trial.
JAMA Psychiatry, 75(3), 233–239. https://doi.org/10.1001/jamap
sychiatry.2017.4249
Smith-Apeldoorn, S. Y., Veraart, J. K., & Schoevers, R. A. (2019).
Definition and epidemiology of treatment resistance in psychiatry.
In Y. K. Kim (Ed.), Treatment resistance in psychiatry (pp. 3–24).
Singapore: Springer. https://doi.org/10.1007/978-981-10-4358-1_1
|
35 of 36
Sippel, L. M., Holtzheimer, P. E., Friedman, M. J., & Schnurr, P. P.
(2018). Defining treatment-resistant posttraumatic stress disorder:
A framework for future research. Biological Psychiatry, 84(5), e37–
e41. https://doi.org/10.1016/j.biopsych.2018.03.011
Stenmark, H., Catani, C., Neuner, F., Elbert, T., & Holen, A. (2013).
Treating PTSD in refugees and asylum seekers within the general
health care system. A randomized controlled multicenter study.
Behaviour Research and Therapy, 51(10), 641–647. https://doi.
org/10.1016/j.brat.2013.07.002
Steenkamp, M. M., Litz, B. T., Hoge, C. W., & Marmar, C. R. (2015).
Psychotherapy for military-related PTSD: A review of randomized clinical trials. JAMA, 314, 489–500. https://doi.org/10.1001/
jama.2015.8370
Stefanovics, E. A., Rosenheck, R. A., Jones, K. M., Huang, G., &
Krystal, J. H. (2018). Minimal clinically important differences
(MCID) in assessing outcomes of post-traumatic stress disorder.
Psychiatric Quarterly, 89(1), 141–155. https://doi.org/10.1007/
s11126-017-9522-y
Tarrier, N., Pilgrim, H., Sommerfield, C., Faragher, B., Reynolds,
M., Graham, E., & Barrowclough, C. (1999). A randomized
trial of cognitive therapy and imaginal exposure in the treatment of chronic posttraumatic stress disorder. Journal of
Consulting and Clinical Psychology, 67(1), 13–18. https://doi.
org/10.1037//0022-006x.67.1.13
ter Heide, F. J. J., Mooren, T. M., Kleijn, W., de Jongh, A., & d., &
Kleber, R. J., (2011). EMDR versus stabilisation in traumatised
asylum seekers and refugees: Results of a pilot study. European
Journal of Psychotraumatology, 2(1), 5881. https://doi.org/10.3402/
ejpt.v2i0.5881
ter Heide, F. J. J., Mooren, T. M., Van de Schoot, R., De Jongh, A.,
& Kleber, R. J. (2016). Eye movement desensitisation and reprocessing therapy v. stabilisation as usual for refugees: Randomised
controlled trial. The British Journal of Psychiatry, 209(4), 311–318.
https://doi.org/10.1192/bjp.bp.115.167775
Triffleman, E. (2000). Gender differences in a controlled pilot study
of psychosocial treatments in substance dependent patients with
post-traumatic stress disorder: Design considerations and outcomes.
Alcoholism Treatment Quarterly, 18(3), 113–126. https://doi.
org/10.1300/J020v18n03_10
Tucker, P., Zaninelli, R., Yehuda, R., Ruggiero, L., Dillingham, K., &
Pitts, C. D. (2001). Paroxetine in the treatment of chronic posttraumatic stress disorder: Results of a placebo-controlled, flexible-dosage trial. The Journal of Clinical Psychiatry, 62, 860–868. https://
doi.org/10.4088/jcp.v62n1105
Tuerk, P. W., Wangelin, B. C., Powers, M. B., Smits, J. A. J., Acierno,
R., Myers, U. S., … Hamner, M. B. (2018). Augmenting treatment
efficiency in exposure therapy for PTSD: A randomized double-blind placebo-controlled trial of yohimbine HCl. Cognitive
Behaviour Therapy, 47(5), 351–371. https://doi.org/10.1080/16506
073.2018.1432679
van den Berg, D. P., de Bont, P. A., van der Vleugel, B. M., de Roos,
C., de Jongh, A., Van Minnen, A., & van der Gaag, M. (2015).
Prolonged exposure vs eye movement desensitization and reprocessing vs waiting list for posttraumatic stress disorder in patients with
a psychotic disorder: A randomized clinical trial. JAMA Psychiatry,
72(3), 259–267. https://doi.org/10.1001/jamapsychiatry.2014.2637
van Denderen, M., de Keijser, J., Stewart, R., & Boelen, P. A. (2018).
Treating complicated grief and posttraumatic stress in homicidally bereaved individuals: A randomized controlled trial. Clinical
36 of 36
|
Psychology & Psychotherapy, 25(4), 497–508. https://doi.
org/10.1002/cpp.2183
van der Kolk, B. A., Spinazzola, J., Blaustein, M. E., Hopper, J. W.,
Hopper, E. K., Korn, D. L., & Simpson, W. B. (2007). A randomized clinical trial of eye movement desensitization and reprocessing
(EMDR), fluoxetine, and pill placebo in the treatment of posttraumatic stress disorder: Treatment effects and long-term maintenance.
Journal of Clinical Psychiatry, 68(1), 37–46.
Veritas Health Innovation. Covidence systematic review software.
Retrieved from www.covidence.org
Wang, P. S., Lane, M., Olfson, M., Pincus, H. A., Wells, K. B., &
Kessler, R. C. (2005). Twelve-month use of mental health services
in the United States: Results from the National Comorbidity Survey
Replication. Archives of General Psychiatry, 62(6), 629–640.
https://doi.org/10.1001/archpsyc.62.6.629
Weathers, F. W., Keane, T. M., & Davidson, J. R. (2001). Clinicianadministered PTSD Scale: A review of the first ten years of research.
Depression and Anxiety, 13(3), 132–156. https://doi.org/10.1002/
da.1029
Wells, A., Walton, D., Lovell, K., & Proctor, D. (2015). Metacognitive
therapy versus prolonged exposure in adults with chronic
post-traumatic stress disorder: A parallel randomized controlled
trial. Cognitive Therapy and Research, 39(1), 70–80. https://doi.
org/10.1007/s10608-014-9636-6
Yehuda, R., & Hoge, C. W. (2016). The meaning of evidence-based
treatments for veterans with posttraumatic stress disorder. JAMA
Psychiatry, 73(5), 433–434. https://doi.org/10.1001/jamapsychi
atry.2015.2878
Yehuda, R., Bierer, L. M., Pratchett, L. C., Lehrner, A., Koch, E. C., Van
Manen, J. A., … Hildebrandt, T. (2015). Cortisol augmentation of
a psychological treatment for warfighters with posttraumatic stress
disorder: Randomized trial showing improved treatment retention
and outcome. Psychoneuroendocrinology, 51, 589–597. https://doi.
org/10.1016/j.psyneuen.2014.08.004
Yehuda, R., Pratchett, L. C., Elmes, M. W., Lehrner, A., Daskalakis, N.
P., Koch, E., … Bierer, L. M. (2014). Glucocorticoid-related predictors and correlates of post-traumatic stress disorder treatment response in combat veterans. Interface Focus, 4(5), 20140048. https://
doi.org/10.1098/rsfs.2014.0048
VARKER ET AL.
Yuen, E. K., Gros, D. F., Price, M., Zeigler, S., Tuerk, P. W., Foa, E. B.,
& Acierno, R. (2015). Randomized controlled trial of home-based
telehealth versus in-person prolonged exposure for combat-related PTSD in veterans: Preliminary results. Journal of Clinical
Psychology, 71(6), 500–512. https://doi.org/10.1002/jclp.22168
Ziemba, S. J., Bradley, N. S., Landry, L.-A.- P., Roth, C. H., Porter,
L. S., & Cuyler, R. N. (2014). Posttraumatic stress disorder treatment for Operation Enduring Freedom/Operation Iraqi Freedom
combat veterans through a civilian community-based telemedicine
network. Telemedicine and e-Health, 20(5), 446–450. https://doi.
org/10.1089/tmj.2013.0312
Zoellner, L. A., Feeny, N. C., Fitzgibbons, L. A., & Foa, E. B. (1999).
Response of African American and Caucasian women to cognitive
behavioral therapy for PTSD. Behavior Therapy, 30(4), 581–595.
https://doi.org/10.1016/S0005-7894(99)80026-4
Zoellner, L. A., Roy-Byrne, P. P., Mavissakalian, M., & Feeny, N. C.
(2018). Doubly randomized preference trial of prolonged exposure versus sertraline for treatment of PTSD. American Journal of Psychiatry,
176(4), 287–296. https://doi.org/10.1176/appi.ajp.2018.17090995
Zohar, J., Amital, D., Miodownik, C., Kotler, M., Bleich, A., Lane, R.
M., & Austin, C. (2002). Double-blind placebo-controlled pilot
study of sertraline in military veterans with posttraumatic stress
disorder. Journal of Clinical Psychopharmacology, 22(2), 190–195.
https://doi.org/10.1097/00004714-200204000-00013
SUPPORTING INFORMATION
Additional supporting information may be found online in
the Supporting Information section.
How to cite this article: Varker T, Kartal D, Watson
L, et al. Defining response and nonresponse to
posttraumatic stress disorder treatments: A systematic
review. Clin Psychol Sci Pract. 2020;00:e12355.
https://doi.org/10.1111/cpsp.12355